38th Annual Meeting
American Society for Histocompatibility and Immunogenetics

Final Program
San Juan, Puerto Rico • Puerto Rico Convention Center
October 8 – 12, 2012

www.ashi-hla.org
Thank You to the 2012 ASHI Corporate Supporters

Abbott Molecular
Art Robbins Instruments
Bio-Rad Laboratories
Elsevier
GenDx
HOLOGIC | Gen-Probe
Histogenetics
Life Technologies
Linkage Biosciences, Inc.
MLC Group, LLC
National Marrow Donor Program
Olerup, Inc.
One Lambda, Inc.
Promega Corporation
Roche Diagnostics
STEMCELL Technologies, Inc.
SystemLink, Inc.
Table of Contents

General Information ..................................... 5
ASHI Program Planning Committee . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
Abstract Reviewers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
Board of Directors ....................................... 13
Corporate Supporters ................................... 15
Exhibitor Directory ..................................... 16
Award Winners ......................................... 26
Schedule at a Glance .................................... 33
Abstracts ............................................. 40
Hotel & Exhibit Floor Plans ......................... 86
General Information

Registration
Registration is located in the Exhibit Hall C Foyer on Level 1.

- **Monday, October 8**: Noon – 7:00 PM
- **Tuesday, October 9**: 7:00 AM – 4:00 PM
- **Wednesday, October 10**: 7:30 AM – 6:00 PM
- **Thursday, October 11**: 8:00 AM – 6:00 PM
- **Friday, October 12**: 8:00 AM – 10:30 AM

Speaker Ready Room
The Speaker Ready Room is located in room 211 on Level 2.

- **Monday, October 8**: 5:00 PM – 7:00 PM
- **Tuesday, October 9**: 7:00 AM – 4:00 PM
- **Wednesday, October 10**: 7:00 AM – 4:30 PM
- **Thursday, October 11**: 7:00 AM – 4:30 PM
- **Friday, October 12**: 7:30 AM – 10:30 AM

Exhibits/Internet Café
Exhibits and the Internet Café are located in Exhibit Hall C on Level 1.

Exhibit and Poster Viewing Hours

- **Tuesday, October 9**: 10:00 AM – Noon
  2:00 PM – 7:00 PM
- **Wednesday, October 10**: 10:00 AM – Noon
  2:00 PM – 5:30 PM
- **Thursday, October 11**: 10:00 AM - Noon

Poster Mounting Times

- **Monday, October 8**: 3:00 PM – 7:00 PM
- **Tuesday, October 9**: 7:00 AM – 9:00 AM

Poster Dismounting Time

- **Thursday, October 11**: Noon – 2:00 PM
  (Any poster still in place at 2:00 PM will be discarded)
General Information

ADA Compliance
ASHI fully complies with the legal requirements of the Americans with Disabilities Act rules and regulations. If any participant is in need of special accommodations, please notify the hotel and indicate the type of assistance needed. ASHI cannot ensure the availability of appropriate assistance without advance notice.

Cameras and Cell Phones
No cameras of any kind are permitted inside education session rooms. Any violation of this policy may result in the offender being removed from the meeting. As a courtesy to fellow attendees, please turn off cell phones during educational sessions.

Meeting Objectives
The 38th Annual Meeting has been designed to provide participants with a comprehensive review of all of the parameters that govern the pre- and post-transplant management of solid organ and hematopoietic stem cell transplant recipients. Keynote and daily introductory lectures will set the stage for plenary sessions focusing on today’s key issues in advancing the fields of histocompatibility and immunogenetics. Emphasis will be placed on the development and use of immunogenetic markers for monitoring allograft acceptance or rejection, and high throughput analysis of the human MHC in clinical settings, including cases involving infectious diseases. Companion symposia will follow each plenary session to provide more in-depth information in those areas. These sessions will explore the ontogeny of B cells and antibody production, the role of B cells in immunoregulation of hematopoietic stem cell and solid organ transplants, the use of genomic or other nucleic acid information to evaluate graft stability and function, progression of viral disease, MHC haplotype variability and haplo-identical stem cell transplants.

The workshop sessions have been constructed to provide participants with practical information on the current trends in histocompatibility, immunogenetics, and immunology, and will integrate this information with the principles and technologies discussed in the didactic sessions. Workshops include standardization in reporting antibody fluorescence, applying histocompatibility data in transfusion medicine, advances in crossmatching techniques, and analysis of epitopes as a means to determine compatibility. Case studies in solid organ and stem cell transplantation will provide practical approaches on how this information can be utilized for pre- and post-transplant patient management.

After attending this meeting, participants will be able to identify the role of B cells and antibodies in host acceptance or rejection of a graft and the tools necessary to define and monitor them. Participants will be able to recognize the key elements in developing a culture of excellence in the clinical laboratory and the metrics used to assess its performance. Participants will also receive state of the art information on the use of genomic and proteomic approaches to pre- and post-transplant graft management and how to adapt them to ensure better patient outcomes.
Evaluation

Participants must complete an evaluation form in order to receive a certificate documenting credits earned for attending sessions. Sessions must be attended in their entirety. Partial credit is not available. Following the meeting, complete the evaluation and print your certificate by visiting www.cmecertificateonline.com. Online meeting evaluations will be available from October 12 – November 12, 2012, after which time certificates will no longer be available.

Physicians

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Institute for the Advancement of Human Behavior (IAHB) and the American Society for Histocompatibility & Immunogenetics. The IAHB is accredited by the ACCME to provide continuing medical education for physicians.

AMA PRA Statement

The IAHB designates this live activity for a maximum of 31.5 PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CHT, CHS, ABHI Diplomates

The American Board of Histocompatibility and Immunogenetics has approved the 38th Annual Meeting content for a maximum of 31.5 contact hours and 4.725 continuing education credits (CEC); and has approved the Inspectors’ Training Workshop content for a maximum of 7.5 contact hours and 1.125 CEC, applicable for Certified Histocompatibility Technologists (CHT), Certified Histocompatibility Specialists (CHS), and ABHI Diplomates.

Abstract Awards

The following awards will be presented to the highest ranked abstracts accepted for oral presentations: ASHI Scholars, International Scholar, Best Solid Organ Case Study and Best Stem Cell Case Study. Three posters will be awarded the following: President’s Choice, Best Visual and Most Innovative.

Internet Café – Supported by Abbott Molecular

Complimentary computer stations are provided enabling you to access the Internet. The Internet Café is located in Exhibit Hall C on Level 1. Use of these computers is limited to 15 minutes.
Convention Center Information

Business Center
The on-site Business Center is conveniently located on Level 1 of the Convention Center. The hours of operation are Monday through Friday, 9:00 AM – 5:00 PM. Services and products include: computer rental, printing, secretarial service, copying, fax transmission and receipt, package shipping, office products, and other services.

Concession Stands
The Puerto Rico Convention Center’s concession stands will be open during breakfast and lunch for your convenience.

Hours of Operations
Monday – Thursday 6:30 AM – 5:00 PM
Friday 6:30 AM – Noon

Hotel Information
The Sheraton Puerto Rico Hotel & Casino offers a variety of restaurants to choose from.

Choices
An indoor or al fresco eatery, serving breakfast, lunch and dinner daily. Featuring traditional favorites with a creative twist, Choices provides a sophisticated yet casual and comfortable atmosphere that is ideal for any number of occasions or gatherings.

Hours:
Breakfast: Monday – Friday 6:30 AM – 11:00 AM
Lunch: Monday – Friday 11:00 AM – 3:00 PM
Dinner: Saturday – Thursday 6:00 PM – 10:00 PM
Friday & Saturday 6:00 PM – 11:00 PM

District Bar
The perfect spot for a drink and quiet conversation. Succulent small bites from the tapas menu are offered in this relaxed setting that reaches from the lobby lounge to the outdoor terrace.

Hours:
Sunday – Wednesday Noon – 1:00 AM
Thursday – Saturday Noon – 2:00 AM

Pool Bar & Grille
Enjoy a bayside lunch or light snack or relax and unwind with a cocktail as the sun sets. The Bayfront Grill serves an array of gourmet Caribbean-influenced cuisine, including sandwiches, burgers, wraps and salads, in a casual setting.

Hours:
Sunday – Thursday 11:00 AM – 6:00 PM
Friday & Saturday 11:00 AM – Midnight (with live entertainment Friday & Saturday evenings)
Program Planning Committee

Program Planning Chair
Geoffrey Land, PhD, HCLD
The Methodist Hospital
Weill Cornell Medical College

Plenary and Symposia Sessions
Marcelo Fernández-Viña, PhD, D(ABHI)
Stanford University School of Medicine

John A. Gerlach, PhD, D(ABHI)
Michigan State University

Amy Hahn, PhD, D(ABHI)
Albany Medical College

William Hildebrand, PhD, D(ABHI)
University of Oklahoma
Health Science Center

Malek Kamoun, MD, PhD
University of Pennsylvania

Cathi Murphey, PhD
Southwest Immunodiagnosics, Inc.

Donna Phelan, BA, CHS, MT(HEW)
Barnes-Jewish Hospital

Phillip Ruiz, MD, PhD
University of Miami
Miller School of Medicine

Elizabeth Trachtenberg, MS, PhD, D(ABHI)
Children’s Hospital & Research Center at Oakland

Abstracts Chairs
Patricia Campbell, MBChB, MRCP(UK), F
University of Alberta Hospitals

Sallyanne Fossey, PhD, D(ABHI)
DCI Laboratory

Shalini Pereira, PhD, D(ABHI)
Seattle Cancer Care Alliance

Workshops Chairs
Nebila Abdulwahab, MT(ASCP), CHT
Ohio State University Hospital

Walter Herczyk, MT(ASCP), CHS
University of Chicago Medical Center

David Partlow, MS, MT, CHS
MD Anderson Cancer Center

Continuing Medical Education
Accreditation Manager
Jillian Davis
SmithBucklin Corporation
Abstract Reviewers

Moheeb Al-Awwami, PhD, CHT, CHS  
King Faisal Hospital Specialist Hospital & Research Centre

Medhat Askar, MD, PhD, D(ABHI)  
Allogen Laboratories

Lee Ann Baxter-Lowe, PhD, D(ABHI)  
University of California San Francisco

Noureddine Berka, PhD, D(ABHI)  
Calgary Laboratory Services

Rainer Blaszyk, MD, PhD  
Hannover Medical School

Benita Book, CHT, CHS  
Indiana University

Robert Bray, PhD, D(ABHI)  
Emory University Hospital

Patricia Campbell, MBChB, MRCP(UK), F  
University of Alberta Hospitals

Michael J. Cecka, PhD, D(ABHI)  
University of California Los Angeles

Pam Chapman, MT(ASCP)  
Emory University Hospital

James Cicciarelli, PhD  
National Institute of Transplantation

Frans Claas, PhD  
Leiden University Medical Center

Daniel Cook, PhD, D(ABHI)  
UT Houston Health Science Center

Deborah Crowe, PhD, D(ABHI)  
DCI Laboratory

Steven De Goey, BS, CHS  
Mayo Clinic

Julio Delgado, MD, MS, D(ABHI)  
University of Utah

Nicholas DiPaola, PhD  
Ohio State University Medical Center

Ronald Domen, MD  
Penn State Milton S. Hershey Medical Center

Ilias Doxiadis, PhD  
Leiden University Medical Center

David Eckels, PhD, D(ABHI)  
The University of Utah

Geyhad El Ghazali, MD, PhD, D(AMBLI), FASCP  
King Fahad Medical City

Thomas Ellis, PhD, D(ABHI)  
Blood Center Southeast Wisconsin

Cindy Ellison, PhD, D(ABHI)  
University of Manitoba

Moe Elrefaei, MD, PhD  
Puget Sound Blood Center

Sallyanne Fossey, PhD, D(ABHI)  
DCI Laboratory

Sujata Gaitonde, MD  
University of Illinois at Chicago

Manish Gandhi, MD  
Mayo Clinic

Ketevan Gendzekhadze, PhD  
City of Hope

Maria Gerbase-De Lima, MD, PhD  
Federal University of San Paulo

David Gjertson, PhD  
University of California Los Angeles

Clara Gorodezky, DSc, PhD  
InDRE, SSA

Amy Hahn, PhD, D(ABHI)  
Albany Medical College

Gregory Hale, MD  
All Children’s Hospital

John Hart, CHS, MBA  
Johns Hopkins University, School of Medicine
Abstract Reviewers

Gabriella Henel, PhD  
Piedmont Hospital

William Hildebrand, PhD, D(ABHI)  
University of Oklahoma Health Science Center

Susan Hsu, D(ABHI)  
American Red Cross Blood Services  
Penn-Jersey Region

Charlene Hubbell, BS, MT(ASCP), SBB  
Health Science Center

Annette Jackson, PhD  
Johns Hopkins University School of Medicine

Malek Kamoun, MD, PhD  
University of Pennsylvania

Siva Kanangat, PhD  
St. Jude Children’s Research Hospital

Ronald Kerman, PhD  
Baylor College of Medicine

Pamela Kimball, PhD, HCLD  
Medical College of Virginia

William Klitz, PhD  
University of California, School of Public Health

Ellen Klohe, PhD, D(ABHI)  
Inland Northwest Blood Center

Chantal Lacelle, MD, PhD  
University of Texas Southwest Medical Center

Jar-How Lee, PhD, D(ABHI)  
One Lambda, Inc.

Mary Sue Leffell, PhD, AMBMLI, D(ABHI)  
Johns Hopkins University, School of Medicine

Curt Lind, CHS  
Children’s Hospital of Philadelphia, Immunogenetics Laboratory

Mayra Lopez-Cepero, PhD, D(ABHI)  
LifeLink Foundation

Lucie Richard, PhD  
Hema-Quebec

James M. Mathew, PhD  
Northwestern University, Feinberg School of Medicine

Narinder Mehra, PhD  
All-India Institute of Medical Sciences

Derek Middleton, DSc, PhD, FRC, PATH  
Royal Liverpool University Hospital

Joshua Miller, MD  
Northwestern University, Feinberg School of Medicine

Thalachallour Mohanakumar, PhD, D(ABHI)  
Washington University School of Medicine

Dimitri Monos, PhD  
University of Pennsylvania, Children’s Hospital of Pennsylvania

Gerald Morris, MD, PhD  
Washington University School of Medicine

Omar Moussa, PhD  
Medical University of South Carolina, Pathology & Laboratory Medicine

Mehra Narinder, PhD  
All-India Institute of Medical Sciences

Peter Nickerson, MD, FRCPC  
Canadian Blood Services

Allen Norin, PhD, D(ABHI)  
SUNY Downstate Medical Center

Paul Norman, PhD  
Stanford University

Carol Pancoska, PhD, D(ABHI)  
Community Blood Services

Noemi Pereira, PhD  
Universidade Federal do Paraná

Shalini Pereira, PhD, D(ABHI)  
Fred Hutchinson Cancer Research Center
Abstract Reviewers

Donna Phelan, BA, CHS, MT(HEW)  
Barnes-Jewish Hospital

Michele Prod, BS, MT(ASCP), CHS  
Rush University Medical Center

Rajalingam Raja, PhD  
UCLA Immunogenetics Center

Sandra Resto-Ruiz, PhD, HCLD(ABB)  
LifeLink Foundation

Jerry Rosenberg, MD, PhD  
Gift of Life Michigan

Jennifer Schiller, PhD  
Blood Center of Wisconsin

David Senitzer, PhD, D(ABHI), ABMLI  
City of Hope National Medical Center

Hiroko Shike, MD  
Penn State Hershey Medical Center

Peter Stastny, MD  
University of Texas Southwestern Medical Center

Brian Susskind, PhD, MS, BA, D(ABHI)  
University of Cincinnati

Anat Tambur, DMD, PhD, D(ABHI)  
Northwestern University

Gary Teresi, MT, CHS  
Allogen Laboratories

Mohanakumar Thalachallour, PhD, D(ABHI)  
Washington University School of Medicine

Marcel G.J. Tilanus, PhD  
Maastricht University Medical Centre

Kathryn Tinckam, MD  
University Health Network

Elizabeth Trachtenberg, MS, PhD, D(ABHI)  
Children’s Hospital Oakland Research Institute

Victoria Turner, PhD, D(ABHI)  
St. Jude Children’s Research Hospital

George Vlad, PhD  
Columbia University

Danny Youngs, BS, CHS  
Puget Sound Blood Center

Andrea Zachary, PhD, D(ABHI)  
Johns Hopkins University, School of Medicine

Adriana Zeevi, PhD, D(ABHI)  
University of Pittsburgh Medical Center
2012 Board of Directors

2012 Executive Committee

President
Amy Hahn, PhD, D(ABHI) (2012)
Albany Medical College
Transplant Immunology Lab, MC 122
47 New Scotland Avenue
Albany, NY 12208
Phone: (518) 262-5574
Fax: (518) 262-6274
hahna@mail.amc.edu

President Elect
Marilyn S. Pollack, PhD, D(ABHI) (2012)
University of Texas Health Science Center
Department of Pathology
7703 Floyd Curl Drive
San Antonio, TX 78229
Phone: (210) 567-5698
Fax: (210) 358-0777
pollack@uthscsa.edu

Past President
Geoffrey Land, PhD, HCLD (2012)
The Methodist Hospital
Weill Cornell Medical College
HLA & Transplant Immunology
6565 Fannin Street B280
Houston, TX 77030
Phone: (713) 441-0424
Fax: (713) 441-0489
gland@tmhs.org

Vice President of Operations
Judy E. Baker, CHS, I(ASCP) (2014)
Baylor University Medical Center
3500 Gaston Avenue
L-0470, Y-Wing
Dallas, TX 75246
Phone: (214) 820-8863
Fax: (214) 820-6384
judyba@baylorhealth.edu

Secretary
Dorothy M. Levis, MT(ASCP), CHS(ABHI) (2013)
Gift of Life Michigan
3861 Research Park Drive
Ann Arbor, MI 48108
Phone: (734) 922-1056
Fax: (734) 973-0332
dlevis@giftoflifemichigan.org

Treasurer
Doreen A. Jezek, MS, CHS, MB(ASCP)SM (2012)
University of Kentucky
ImmunoMolecular Pathology Laboratory
800 Rose Street, HA629
Lexington, KY 40536
Phone: (859) 257-4583
Fax: (859) 257-0029
doreen.jezek@uky.edu
2012 Board of Directors

Elizabeth R. Trimble, MT(ASCP), CHS(ABHI) (2012)
Via Christi Regional Medical Center
#3653 929 N St Francis
HLA Laboratory
Wichita, KS 67214
Phone: (316) 268-5447
Elizabeth_Trimble@via-christi.org

Maria Bettinotti, PhD, D(ABHI) (2013)
Quest Diagnostics Nichols Institute
14225 Newbrook Drive
HLA and Immunogenetic
Chantilly, VA 20151
Phone: (703) 802-7254
maria.p.bettinotti@questdiagnostics.com

John A. Gerlach, PhD, D(ABHI) (2013)
Michigan State University
B228 Life Science Building
East Lansing, MI 48824
Phone: (517) 432-3467
gerlach@msu.edu

Joannis Mytilineos, MD, PhD (2013)
Und Immugenetik (IKT) GGmbH
Leiter Der Abt
Tansplantations Immunologist
Helmholtzstrabe 10
D-89081 ULM – GERMANY
Phone: 49-731-150 524
j.mytilineos@blutspende.de

Walter Herczyk, MT(ASCP), CHS (2014)
University of Chicago Medical Center
Transplant Immunology & Immunogenetics
Laboratory
MC0006 Room: G320
5841 South Maryland Avenue
Chicago, IL 60637-1470
Phone: (773) 702-5388
walter.herczyk@uchospitals.edu

Malek Kamoun, MD, PhD (2014)
University of Pennsylvania
3400 Spruce Street HUP
7.020 Founders Pavilion Department
Pathology
Philadelphia, PA 19104
Phone: (215) 662-4022
malekkam@mail.med.upenn.edu

Lorita Rebellato-De Vente, PhD, MS, D(ABHI) (2014)
ECU Brody School of Medicine
600 Moye Boulevard, Room 7S18
Department of Pathology & Laboratory Medicine
Brody Building Room 7590
Greenville, NC 27858
Phone: (252) 744-4986
rebellatol@ecu.edu

Dawn R. Wagenknecht, MS, CHS (2014)
St. Francis Hospital
1500 Albany Street, Room 1109
HLA Vascular-Biology Laboratory
Beech Grove, IN 46107
Phone: (317) 782-7187
Dawn.Wagenknecht@franciscanalliance.org
Corporate Supporters

**Diamond Level**
- Life Technologies
  *(Lanyards)*
- One Lambda, Inc.
  *(Unrestricted Educational Grant)*

**Platinum Level**
- Abbott Molecular
  *(Internet Café)*
- HOLOGIC | Gen-Probe
  *(Final Program Printing)*

**Gold Level**
- Histogenetics
  *(Registration Bags)*

**Silver Level**
- Olerup, Inc.
  *(Water Bottles)*
- Roche Diagnostics
  *(Notepads)*

**Bronze Level**
- Bio-Rad Laboratories
  *(Distinguished Scientist Award)*
- Elsevier
  *(International Scholar Award)*
- GenDx
- Linkage Biosciences, Inc.
  *(Distinguished Service Award)*
- National Marrow Donor Program
  *(Outstanding Technologist Award)*
- Promega Corporation
  *(ASHI Scholar Award)*
- STEMCELL Technologies, Inc.
  *(ASHI Scholar Award)*

**Friends of ASHI**
- Art Robbins Instruments
- MLC Group, LLC
  *(Outstanding Technologist Dinner)*
- SystemLink, Inc.
Exhibit Information

Exhibitor Booth Numbers

<table>
<thead>
<tr>
<th>Exhibitor Company Descriptions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott Molecular 200, 201</td>
</tr>
<tr>
<td>American Foundation</td>
</tr>
<tr>
<td>for Donation &amp; Transplantation 107</td>
</tr>
<tr>
<td>ASHI Membership 109</td>
</tr>
<tr>
<td>Bio-Rad Laboratories 411</td>
</tr>
<tr>
<td>CEDARLANE 513</td>
</tr>
<tr>
<td>chemagen from PerkinElmer 202</td>
</tr>
<tr>
<td>Cylex 510</td>
</tr>
<tr>
<td>DiaSorin, Inc. 305</td>
</tr>
<tr>
<td>DNA Genotek 509</td>
</tr>
<tr>
<td>Embi-Tec 210</td>
</tr>
<tr>
<td>GenDx 415</td>
</tr>
<tr>
<td>GenTrak, Inc. 315</td>
</tr>
<tr>
<td>Histogenetics 209</td>
</tr>
<tr>
<td>HOLOGIC</td>
</tr>
<tr>
<td>LabCorp 511</td>
</tr>
<tr>
<td>LABS, Inc. 101</td>
</tr>
<tr>
<td>Life Technologies 501</td>
</tr>
<tr>
<td>Linkage Biosciences, Inc. 307</td>
</tr>
<tr>
<td>National Marrow Donor Program 103</td>
</tr>
<tr>
<td>Olerup, Inc. 400</td>
</tr>
<tr>
<td>One Lambda, Inc. 401</td>
</tr>
<tr>
<td>Path-Tec 404</td>
</tr>
<tr>
<td>Promega Corporation 512</td>
</tr>
<tr>
<td>PROTRANS 212</td>
</tr>
<tr>
<td>Qiagen 206</td>
</tr>
<tr>
<td>Roche Diagnostics 208</td>
</tr>
<tr>
<td>STEMCELL Technologies, Inc. 406</td>
</tr>
<tr>
<td>SystemLink, Inc. 301</td>
</tr>
<tr>
<td>Trans-Type Diagnostics 214</td>
</tr>
</tbody>
</table>

Exhibitor Company Descriptions

Abbott Molecular 200, 201

1300 East Touhy Avenue
Des Plaines, IL 60018
Phone: (800) 553-7042
www.abbottmolecular.com

Abbott Molecular is a leader in molecular diagnostics for the analysis of DNA, RNA, and proteins. Our instruments and reagents detect pathogens and subtle changes in patients’ genes and chromosomes, permitting earlier diagnosis, the selection of appropriate therapies and improved monitoring of disease progression.
American Foundation for Donation & Transplantation  

8154 Forest Hill Avenue  
Suite 3  
Richmond, VA 23235  
Phone: (804) 323-9893  
E-mail: skinner@seopf.org  
www.amfdt.org

The American Foundation for Donation & Transplantation, formerly SEOPF, is the continuation of the oldest transplantation and donation professional organization in the United States. Founded in 1969 in Richmond, Virginia by Drs. David Hume and Bernard Amos, SEOPF gave rise to UNOS and now has become the AFDT. www.amfdt.org (800)-KIDNEY9.

American Society for Histocompatibility & Immunogenetics  

15000 Commerce Parkway  
Suite C  
Mount Laurel, NJ 08054  
Phone: (856) 638-0428  
E-mail: info@ashi-hla.org  
www.ashi-hla.org

The American Society for Histocompatibility and Immunogenetics (ASHI) is a not-for-profit association of clinical and research professionals including immunologists, geneticists, molecular biologists, transplant physicians and surgeons, pathologists and technologists. As a professional society involved in histocompatibility, immunogenetics and transplantation, ASHI is dedicated to advancing the science and application of histocompatibility and immunogenetics; providing a forum for the exchange of information; and advocating the highest standards of laboratory testing in the interest of optimal patient care.

Bio-Rad Laboratories  

4000 Alfred Nobel Drive  
Hercules, CA 94547  
Phone: (510) 724-7000  
E-mail: diagcs@bio-rad.com  
www.bio-rad.com

Bio-Rad offers a complete line of industry standard HLA Serology Typing Trays (Lymphotype); Serological (Lymphoscreen) and ELISA-based (AbScreen/AbIdent*) Antibody Diagnostics Systems; Molecular Typing Systems (SSO and SSP) with full automation platforms; Immune Monitoring, Infectious Disease and Traditional Blood Group Serology Products to meet your laboratory needs.  

*Not available in US.
Exhibitor Company Descriptions (continued)

CEDARLANE 513

1210 Torrentine Street
Burlington, NC 27215
Phone: (336) 513-5135
E-mail: service@cerdearlanelabs.com
www.cedarlanelabs.com

CEDARLANE is a leading supplier of high quality reagents to the transplant and research communities. We specialize in producing COMPLEMENT for tissue typing and bacteriocidal assays. Other manufactured products include Cedarlane’s Lympholyte® cell separation media, cell purification Immunocolumns and Antibodies including our B and T cell Positive Control Antisera and antibodies to complement components.

chemagen from PerkinElmer 202

940 Winter Street
Waltham, MA 02451
Phone: (800) 762-4000
E-mail: customercareus@perkinelmer.com
www.perkinelmer.com

chemagen is a leading supplier of automation and reagents for fast and reliable magnetic bead based DNA and RNA extraction for sample volumes from 10 ul to 10 ml for blood, tissues, saliva, bacteria, food, PCR products, etc. All functions can be performed on the one instrument. Advantages of this unique system are fast processing, unmatched sample volume range and robust chemistry.

Cylex 510

8980-I Old Annapolis Road
Columbia, MD 21045
Phone: (410) 964-0236
E-mail: contact@cylex.net
www.cylex.net

Cylex is a life sciences company which develops and commercializes in vitro diagnostic products that illuminate immunity. Its patented technology provides an innovative platform to assess immune cell function - providing insight for individualized patient management. ImmuKnow®, the Company’s FDA-cleared product, is used to manage and optimize immunosuppression in transplant patients.
DiaSorin, Inc. 305
1951 Northwestern Avenue
Stillwater, MN 55082
Phone: (800) 328-1482
E-mail: info@diasorin.com
www.diasorin.com

For over 40 years, DiaSorin has been undertaking research and development activities focused on developing innovative reagents, with the aim of developing informative assays addressing unresolved or partially resolved clinical needs. Most recently, through its acquisition of the NorDiag group, DiaSorin gains access to the nucleic acid isolation and cell separation markets. The Arrow instrument is a dual purpose platform, ideally suited to the HLA and Molecular Genetic laboratory market where cost effective DNA preparation and cell separation can be performed with walk away automation. Using established paramagnetic bead chemistry, the Arrow instrument can deplete or enrich a subset of PBMC’s based upon end users specifications.

DNA Genotek 509
2 Beaverbrook Road
Ottawa, ON K2K 1L1
Phone: (613) 723-5757
E-mail: info@dnagenotek.com
www.dnagenotek.com

DNA Genotek is focused on improving nucleic acid sample collection. The company’s Oragene® product line offers registries and researchers a non-invasive, all-in-one system for the collection, stabilization, transportation and purification of high quality DNA from saliva. Oragene’s reliability and ease-of-use have resulted in rapid worldwide adoption by top-tier registries and health institutions.

Embi-Tec 210
7738 Arjons Drive
San Diego, CA 92126
Phone: (858) 684-3190
E-mail: inquiry@embitec.com
www.embitec.com

Embi Tec manufactures and distributes innovative, cost and space effective lab equipment such as the RunOne Electrophoresis System, MultiCaster Systems, ViewOne LabLite (miniature white light box), LightOne Illuminators for setting up and cherry-picking 96 or 384-well plates, PrepOne Sapphire (non-UV, blue light box), PrepOne ImageCatcher and AnyBlood Direct PCR Buffers.
Exhibitor Company Descriptions (continued)

GenDx 415

Yalelaan 48
Utrecht 3593GP, Netherlands
Phone: +31 30 252 3799
E-mail: info@gendx.com
www.gendx.com

GenDx develops and markets innovative certified diagnostic products, software, services and education, providing crucial information for patient-tailored treatments in and beyond transplantation therapy. We strive to make patients benefit from our unique, personal approach to diagnostics.

GenTrak, Inc. 315

121 W. Swannanoa Avenue
P.O. Box 1290
Liberty, NC 27298
Phone: (336) 622-5266
E-mail: sfpresearc@aol.com
www.GenTrakinc.com

GenTrak, Inc. manufactures a quality line of classical HLA serology trays and Frozen Cell trays. HLA serology testing provides quick, cost effective results. Come see our Texas Biogene products that specialize in simple laboratory automation for pre- and post PCR processes. The innovative split well ABCDRDQ in one tray and SBT (Group Specific Primers) can provide unambiguous solutions for your laboratory needs.

Histogenetics 209

300 Executive Boulevard
Ossining, NY 10567
Phone: (914) 762-0300
E-mail: nezih@histogenetics.com
www.histogenetics.com

Histogenetics, based in New York, USA, is an international leader in DNA sequence-based tissue typing (SBT) services and serves clients around the globe. Histogenetics has been developing sophisticated tools by integrating robotics and bio-informatics to provide affordable and the ultimate quality of HLA typing information to the community that could save lives.
## Exhibitor Company Descriptions (continued)

### HOLOGIC | Gen-Probe

<table>
<thead>
<tr>
<th>10210 Genetic Center Drive</th>
</tr>
</thead>
<tbody>
<tr>
<td>San Diego, CA 92121</td>
</tr>
<tr>
<td>Phone: (800) 523-5001</td>
</tr>
<tr>
<td>E-mail: <a href="mailto:marketing@gen-probe.com">marketing@gen-probe.com</a></td>
</tr>
<tr>
<td><a href="http://www.gen-probe.com">www.gen-probe.com</a></td>
</tr>
</tbody>
</table>

Hologic Gen-Probe is a leader in molecular diagnostics used for diagnosing infectious diseases, screening donated blood, assessing immune response for transfusion, measuring components of the coagulation pathway, helping ensure transplant compatibility, and aiding biomedical research/drug development.

### LabCorp

<table>
<thead>
<tr>
<th>1440 York Court Extension</th>
</tr>
</thead>
<tbody>
<tr>
<td>Burlington, NC 27215</td>
</tr>
<tr>
<td>Phone: (800) 533-1037</td>
</tr>
<tr>
<td>E-mail: <a href="mailto:pruittd1@labcorp.com">pruittd1@labcorp.com</a></td>
</tr>
<tr>
<td><a href="http://www.labcorp.com">www.labcorp.com</a></td>
</tr>
</tbody>
</table>

LabCorp operates one of the world’s largest and most experienced HLA testing laboratories providing HLA analysis for stem cell transplants worldwide specializing in SBT, SSP, and SSOP methodologies. Our clients include transplant centers, cord blood banks, bone marrow registries, hospitals and the patients and families they serve. LabCorp is a contract lab for the National Marrow Donor Program (NMDP) and we conduct HLA typing for other registries worldwide. LabCorp is able to provide our clients with the most advanced HLA typing services in the industry through the expertise provided by our experienced doctoral staff and highly trained technical, customer service, and administrative support structure.

### LABS, Inc.

<table>
<thead>
<tr>
<th>6933 B.S. Revere Parkway</th>
</tr>
</thead>
<tbody>
<tr>
<td>Centennial, CO 80112</td>
</tr>
<tr>
<td>Phone: (720) 528-4770</td>
</tr>
<tr>
<td>E-mail: <a href="mailto:rachel_garcia@labs-inc.org">rachel_garcia@labs-inc.org</a></td>
</tr>
<tr>
<td><a href="http://www.labs-inc.org">www.labs-inc.org</a></td>
</tr>
</tbody>
</table>

LABS, Inc. is the leading donor eligibility testing laboratory in the nation. The Company obtained this industry leadership position in the donation community by providing highly customized solutions using the most innovative technologies, delivering precise results, and maintaining an unmatched attention to customer service and quality. The Company is committed to respectfully fulfilling the wishes of donors by ensuring their gifts are quickly and effectively screened so that they may go on to help patients in need.
Exhibitor Company Descriptions (continued)

Life Technologies  
5791 Van Allen Way  
Carlsbad, CA 92008  
Phone: (760) 603-7200  
www.lifetechnologies.com

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company dedicated to moving science forward to improve life in meaningful ways for everyone. Our premier brands are the most cited, most trusted in the life sciences industry: Invitrogen™, Applied Biosystems®, Gibco®, Molecular Probes®, Novex®, TaqMan®, Ambion®, and Ion Torrent™.

Linkage Biosciences, Inc.  
890 Dubuque Avenue  
South San Francisco, CA 94080  
Phone: (415) 346-5262  
E-mail: emitchell@linkagebio.com  
www.linkagebio.com

Introducing LinkSē™ from Linkage Biosciences, the first complete HLA typing product using Real-Time PCR. LinkSēq is the fastest and easiest method available – no more electrophoresis or probing. Less hands on time needed, and provides HLA Typing results, including DP, in under 90 minutes. LinkSēq – Accurate, Fate, Easy HLA Typing.

National Marrow Donor Program  
3001 Broadway Street, NE  
Suite 100  
Minneapolis, MN 55413  
Phone: (612) 627-5892  
E-mail: mmaiers@nmdp.org  
www.marrow.org

NMDP: Bioinformatics Research, Scientific Services & CIBMTR  
We help shape the future of transplantation outcomes, provide HLA expertise and services for international researchers, have the data and expertise you need, and are the scientists for the NMDP. Come along and see how we can help you.
Exhibitor Company Descriptions (continued)

Olerup, Inc. 400

901 S Bolmar Street
Suite R
West Chester, PA 19382
Phone: (877) 653-7871
E-mail: info.us@olerup.com
www.olerup.com

OLERUP - Olerup is a life science company with a focus on transplantation that provides high quality products and services, in order to facilitate safe and effective bone marrow and solid organ transplants. Olerup is the global distributor of innovative molecular diagnostic products and services for transplantation: HLA typing (Olerup SSP® and SBT Resolver™) and for non-HLA antibody detection (XM-ONE®). Olerup’s product offerings are distributed through Olerup, Inc. (Americas) and Olerup GmbH (Rest of World).

One Lambda, Inc. 401

21001 Kittridge Street
Canoga Park, CA 91303
Phone: (818) 702-0042
E-mail: rbrown@onelambda.com
www.onelambda.com

Stop by booth 401 and see all of One Lambda’s latest products, ConsenSys SBT, MicroSSP AmbiStrips, and the new AT1R assay. Plus get a firsthand look at the future of HLA typing with the new next gen SSO platform, LABScan 3D and the all new LABType 3D products. Also, be sure to stop by and get details on our Luncheon Symposium and pick up your wrist band to our annual party hosted this year at Club Brava – the premier nightclub in San Juan.

Path-Tec 404

1333-A Belfast Avenue
Columbus, GA 31904
Phone: (706) 569-6368
www.path-tec.com

Path-Tec is a leading provider of specimen management solutions that include kit design, production, distribution, tracking and software management systems. We understand the importance of specimen integrity so we work with laboratories to design kits that assist with proper specimen collection and protection, meet transportation regulations and include tools to track supplies and specimens. We allow the laboratory to focus on their core competencies while we focus on reducing their time and costs associated with the specimen collection and transport process.
Promega Corporation 512

2800 Woods Hollow Road
Madison, WI 53711
Phone: (608) 298-4842
E-mail: maryjo.martinson@promega.com
www.promega.com

Promega Corporation is a leader in providing innovative solutions to life science, forensic, clinical research and molecular diagnostics markets. Our products consist of kits, reagents and automated platforms. These solutions span the laboratory workflow from nucleic acid purification to amplification to final analysis. The new Maxwell® CSC Instrument, a cGMP compliant nucleic acid extraction system, enhances your laboratory workflow, providing the highest quality output possible and success in critical downstream applications. Stop by the Promega booth to learn more.

PROTRANS 212

Ketschau 2
Hockenheim, 68766
Phone: +49 6205292990
E-mail: mail@protrans.info
www.protrans.info

PROTRANS is a company for research, development and production of Diagnostic Products for Organ- and Bone Marrow Transplantation, located in Germany near Frankfurt and next to the University City of Heidelberg.

Qiagen 206

19300 Germantown Road
Germantown, MD 20874
www.qiagen.com

QIAGEN is the leading global provider of sample and assay technologies that are used to transform biological materials into valuable molecular information. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to four customer classes: Molecular Diagnostics, Academia, Applied Testing, and Pharma.

Roche Diagnostics 208

911 Hague Road
Indianapolis, IN 46250
www.roche-applied-science.com

As part of the larger Roche Diagnostics Corporation, Roche Applied Science supplies a broad and growing array of instruments, reagents, and kits for use in the diverse translational research market. Its product portfolio and capabilities are especially strong in the areas of genomics and cellular analysis - sciences that are transforming our understanding and the treatment of disease.
STEMCELL Technologies, Inc. 406

570 West 7th Avenue
Suite 400
Vancouver, BC V5Z 1B3
Phone: (800) 667-0322
E-mail: info@stemcell.com
www.stemcell.com

STEMCELL Technologies provides fast and easy cell separation solutions for HLA and chimerism analysis, facilitating high-volume sample processing and reliable results. EasySep™ and RosetteSep™ are fast, gentle on cells, and stable at room temperature. SepMate™ isolates PBMCs in just 15 minutes, and RoboSep™ fully automates cell separation, saving technician time and eliminating cross-contamination.

SystemLink, Inc. 301

23475 Rock Haven Way
Suite 140
Dulles, VA 20166
Phone: (703) 651-5706
E-mail: mgunessever@systemlink-inc.com
www.histotrac.com

Visit the SystemLink booth to learn about building a complete, customizable HLA laboratory management system to meet the needs of your laboratory. HistoTrac is a seamless system with flexible design, providing functionality to make data entry and data access quick and easy. New this year – Paired Kidney Exchange module, Platelet Matching module and Matrix-based test ordering. See the HistoTrac software for yourself - in the exhibit hall or in your office.

Trans-Type Diagnostics 214

3513 Urbana Pike
Frederick, MD 21704
Phone: (301) 874-2231
E-mail: ttdhla@aol.com

TRANS-TYPE DIAGNOSTICS provides HLA serological test kits for immunogenetics laboratories throughout the world. Our products are backed by a quarter of a century of experience and offer consistent results with comprehensive antigen coverage. Visit our booth, meet our staff and learn how we can be a valuable resource to your laboratory.
Paul I. Terasaki Clinical Science Award

The Paul I. Terasaki Clinical Science Award was established in 2003 to honor an individual, group, or institution in recognition of significant accomplishments and/or contributions to the fields of clinical transplantation, histocompatibility and immunogenetics. This award was made possible by a grant from the Paul I. Terasaki Foundation.

The winner of the 2012 Paul I. Terasaki Clinical Science Award is:

Denis Glotz, PhD
Hospital St. Louis

Dr. Denis Glotz is Professor of Nephrology, Université Paris V, and Head of the Department of Nephrology and Renal Transplantation, Hôpital Saint-Louis, Paris, France. He is also Head, Transplant Immunology Group, INSERM unit U940, Institut National de la Santé et de la Recherche Médicale, Paris, France.

Dr. Glotz is the author of more than 100 articles in such journals as Kidney International, Transplantation, and Journal of Immunology as well as book chapters and abstracts in the areas of immunology and transplantation. His work focuses on humoral immunity in transplantation, assessment of immunological risk factors and treatment of antibody-mediated lesions. He is a member of the American Society of Nephrology, the American Society of Transplantation, the American Society of Histocompatibility and Immunogenetics, the European Dialysis and Transplantation Association, the French Society of Immunology, the French Society of Nephrology, and the French-speaking Society of Transplantation.

Dr. Glotz received his medical degree from the Faculté de Médecine Saint-Antoine in Paris and a doctoral degree in Immunology, Université Paris VI, where he also completed a research fellowship. Dr. Glotz’s postdoctoral training included an internship at the Hôpitaux de Paris, and residencies in the Department of Nephrology, Hôpital Broussais, Paris. Dr. Glotz also completed research fellowships at the Medical Biology Institute, La Jolla, California, and at the University of California, San Diego, USA.
The Rose Payne Award

The Rose Payne Award was established in 1984 to honor a great scientist and to recognize her longstanding contributions to the field of immunogenetics. As a founding member, Dr. Rose Payne was always willing to share her knowledge and assist others in their endeavors. For more than 30 years, Dr. Payne made significant contributions in areas related to HLA. The Rose Payne Award was established as a tangible recognition of the high regard in which she was held.

The winner of the 2012 Rose Payne Award is:

Elaine F. Reed, PhD, D(ABHI)
UCLA Immunogenetics Center

Dr. Elaine F. Reed is a Professor of Pathology and Laboratory Medicine at the University of California, Los Angeles and the Director of the UCLA Immunogenetics Center. She directs the research and clinical activities of the UCLA Immunogenetics Center and serves as Vice Chair of Research Services for the Department of Pathology and Laboratory Medicine. Prior to joining the UCLA faculty, she was an Associate Professor at Columbia University. Dr. Reed’s research interests over the last 25 years have focused on mechanisms of antibody-mediated acute and chronic allograft rejection. Her recent research studies demonstrated that anti-HLA antibodies can contribute to the development of chronic rejection by triggering intracellular signaling cascades that culminate in endothelial cell and smooth muscle cell survival and proliferation. Her work has delineated the signaling pathways leading to cell proliferation and cell survival, providing the opportunity for the development of therapeutic strategies. Dr. Reed is the recipient of the 1991 Young Investigator Award and 2008 Distinguished Scientist Award from the American Society for Histocompatibility and Immunogenetics. Dr. Reed is an active member of the American Society for Histocompatibility and Immunogenetics, American Association of Immunologists, American Society of Transplantation, Federation of Clinical Immunology Societies, International Society for Heart and Lung Transplantation, and The Transplantation Society. She serves on the editorial boards of Human Immunology, American Journal of Transplantation and Transplant Immunology. Dr. Reed has also served on numerous scientific review groups and consensus panels. Dr. Reed has a track record of NIH funding for the past 22 years and has published extensively in the field of immunogenetics and transplant immunology. Dr. Reed has trained over 50 graduate students, post-doctoral research scientists, clinical fellows and junior faculty in the fields of Immunogenetics and transplant immunology.
ASHI Distinguished Scientist Award

The ASHI Distinguished Scientist Award was established in 2001 to honor a distinguished scientist who is an ASHI member. This individual must have contributed significantly to the field of immunogenetics and/or transplant immunobiology.

The winner of the 2012 ASHI Distinguished Scientist Award is:

Rene Duquesnoy, PhD
University of Pittsburgh
(Award Supported by Bio-Rad Laboratories)

Dr. Rene Duquesnoy was born in the Netherlands where he obtained a M.Sc. degree in chemical engineering from the Technological University of Delft. He received a Ph.D. degree in pathology from the University of Tennessee in Memphis and did a post-doctoral fellowship with Robert A. Good at the University of Minnesota. After his affiliation with the Medical College of Wisconsin and the Blood Center of Wisconsin, in 1984 he became a tenured Professor of Pathology, with joint appointments in Immunology and Surgery at the University of Pittsburgh Medical Center. Until 2006 he was a director of UPMC tissue typing laboratory where he later served as a clinical consultant. Since 2007, he has served as Professor Emeritus of Pathology.

Dr. Duquesnoy’s research deals with HLA and transplantation immunology. His curriculum vitae lists more than 360 publications and 500 scientific presentations at national and international meetings. Milestones include cross-reactive HLA matching in platelet transfusions, the discovery of the MB system (now called HLA-DQ), alloreactivity of graft-infiltrating T-cells, the dualistic role of HLA in liver transplantation, role of stress proteins in transplant immunity and antibody analysis of highly sensitized patients. His current studies deal with a structurally based histocompatibility algorithm called HLAMatchmaker and address the concept of HLA epitope matching in organ transplantation.
ASHI Distinguished Service Award

The ASHI Distinguished Service Award was established in 1999 to honor colleagues who have contributed significantly to serving ASHI.

The winner of the 2012 Distinguished Service Award is:

**Sandra W. Helman, PhD, D(ABHI)**  
Medical College of Georgia Health Systems  
(Award Supported by Linkage Biosciences, Inc.)

Dr. Sandra W. Helman received her undergraduate degree at Miami University in Oxford, Ohio, and her MS and PhD in Microbiology and Immunology at the University of Louisville in the laboratory of John Wallace. She did her postdoctoral fellowship and histocompatibility training at the University of Louisville and at the Jewish Hospital Histocompatibility Laboratory with John Oldfather. She is board certified by the American Board of Histocompatibility and Immunogenetics.

Dr. Helman has served ASHI as a member of the Board of Directors, chair of the Director’s Training and Credentialing Committee, chair of the CPT Task Force and CPT Committee, an abstract reviewer for the annual meeting, and an inspector for the Accreditation Review Board. She is also an inspector for the College of American Pathologists. Through her work with CPT, she was invited to serve on the AMA workgroup that revised the molecular section of the CPT codebook. She was active in the Southeastern Organ Procurement Foundation and has served as the UNOS Region 3 Histocompatibility Representative. She has also served on several ABHI Committees, most recently, the Diplomate Exam Committee.

Dr. Helman is currently Associate Professor of Surgery and Pathology at the Georgia Health Sciences University (formerly the Medical College of Georgia, soon to be Georgia Regents University) where she is also part of the teaching faculty. She has directed the Histocompatibility/Immunology Laboratory for Georgia Health Sciences University Medical Center for the last 22 years. She works closely with the University’s clinical transplant programs.
ASHI Outstanding Technologist Award

The Outstanding Technologist Award has honored some of the most active and creative technologists in the field of HLA. Candidates must have made significant and sustained contributions to ASHI. The Outstanding Technologist Award is dedicated to all ASHI technologists past, present and future for the fine work they do every day in creating better patient outcomes and saving lives.

The winner of the 2012 Outstanding Technologist Award is:

Steven R. De Goey, BS, CHS
Mayo Clinic
(Award Supported by National Marrow Donor Program)

Mr. Steve De Goey, BS, CHS(ABHI) is currently an Assistant Professor of Laboratory Medicine and Pathology in the Mayo Clinic College of Medicine. He is also a Development Coordinator in the HLA Laboratory at the Mayo Clinic in Rochester, Minnesota. Mr. De Goey started his career in Histocompatibility and Immunogenetics as a Tissue Typing Technologist from 1975-1977 at the Milwaukee Blood Center. Professional contributions include ASHI Accreditation Commissioner 1988-1991, ASHI Councilor at Large 1989-1992, ASHI Quality Assurance/Standards Committee 1989-1992, ASHI Annual Program Planning Committee (Educational Workshops, Chair) 1995-1996. In addition, he assisted in organizing and presenting at ASHI Accreditation Program Inspector Training Workshops, served as ASHI Abstract Reviewer 2010-present, and served as both a CAP and ASHI laboratory inspector. Mr. De Goey has taught histocompatibility methods to Medical Technologists, Medicine Residents, Hematology Fellows, Nephrology Fellows, Pathology Residents, and Transfusion Medicine Fellows. He has presented both technical workshops and abstracts at national meetings, and has co-authored over 60 full-length, peer-reviewed articles and abstracts. When not in the laboratory, Mr. De Goey can be found enjoying outdoor sports such as fishing and hunting.
ASHI/SEOPF J. Marilyn MacQueen Award

ASHI has established the ASHI/SEOPF Award honoring J. Marilyn MacQueen. Marilyn was active in immunogenetics and histocompatibility testing since 1964, and was committed to helping young technologists in ASHI or SEOPF-accredited laboratories worldwide. The ASHI/SEOPF J. Marilyn MacQueen Award is presented annually to an outstanding HLA technologist who has worked in the field for less than 36 months and wants to pursue a career in HLA.

The winner of the 2012 J. Marilyn MacQueen Award is:

Sarah N. Schumacher, MLS(ASCP)SM
Barnes Jewish Hospital

Ms. Schumacher grew up on her family’s dairy farm in St. Rose, Illinois. She attended Saint Louis University, and graduated in 2009 with a Bachelor of Science in Clinical Laboratory Science. Sarah now lives in St. Louis, Missouri, where she has worked as a Medical Technologist in the HLA Lab at Barnes-Jewish Hospital (BJH) since July 2009. As one of two technologists on the evening shift in this busy laboratory, Ms. Schumacher performs HLA typing (SSO and SSP), Luminex SA antibody screening, cytotoxic crossmatching, and coordinates deceased donor cases with the OPO and hospital transplant team. She has represented the HLA Lab on the BJH Lab Safety Committee since 2010. In addition, she worked to create a detailed set of guidelines for the HLA Lab when calling allelic and DQA1 antibodies in different situations, which has led to improved consistency of antibodies called between technologists.

At the 2010 ASHI Annual Meeting, Ms. Schumacher gave an oral presentation on her case study titled “Undefined Transient Antibody in a Renal Patient.” At the 2012 Annual Meeting, she is presenting a poster on the effect of serum pre-treatment and C1q on antibody screens and its correlation with cytotoxic crossmatching. Ms. Schumacher enjoys the challenge of learning the intricacies of histocompatibility and looks forward to keeping up with the latest science as this exciting field develops. She feels privileged to be part of the dedicated and passionate group of colleagues around the world who work, learn, research, and teach in the field of histocompatibility and immunogenetics.

Outside the laboratory, Ms. Schumacher enjoys spending time with family and friends, traveling, participating in the American Society for Clinical Laboratory Science (ASCLS), and trying a variety of activities, from basket weaving to rock climbing. She would like to thank her family for all their support and prayers over the years. She also thanks Donna Phelan, Brian Duffy, and all the HLA staff at Barnes-Jewish Hospital for sharing their knowledge and excitement about this field and for their constant support and guidance as she begins her career. Ms. Schumacher is honored and grateful to receive this award and would like to thank the MacQueen Award Committee and ASHI for recognizing the contribution of new HLA technologists.
ASHI Scholars and International Scholar Awards

The best abstracts submitted for the 2012 Annual Meeting will be recognized during the Awards Symposium and the submitters will give an oral presentation during the Special Abstract Scholar Session. These abstracts received the highest rating by the reviewers, and the awards are provided to recognize individuals who made a significant advance in either clinical or basic research areas. The authors were selected from more than 255 submitted abstracts. Recipients receive a monetary award and award plaque for their research.

Special Abstract Session: Scholar Awards
Thursday, October 11 • 2:00 PM – 3:30 PM

David Sayer, PhD - ASHI International Scholar
Connexio Genomics
Fremantle, Australia

Abstract #57-OR: GAMMA-TYPE TM:SIMPLE PCR-SSP’S TO ENABLE THE ASSESSMENT OF HAPLOTYPE MATCHING BETWEEN UNRELATED STEM CELL DONORS AND PATIENTS. (Award Supported by Elsevier)

Marilyn Marrari, BA - ASHI Scholar
University of Pittsburgh School of Medicine
Pittsburgh, PA

Abstract #59-OR: A WEBSITE-BASED INTERNATIONAL REGISTRY OF ANTIBODY-DEFINED HLA EPITOPES. (Award Supported by Promega Corporation)

Curtis McMurtrey, PhD - ASHI Scholar
University of Oklahoma HSC
Oklahoma City, OK

Abstract #58-OR: IMMUNODOMINANT AND SUBDOMINANT WNV PEPTIDE HLA COMPLEXES ARE PRESENTED AT DIFFERENT LEVELS AND ARE TAP DEPENDENT.

Abstract #60-OR: IDENTIFICATION OF NOVEL MYCOBACTERIUM TUBERCULOSIS LIGANDS AND EPITOPES RESTRICTED BY HLA-A2. (Award Supported by STEMCELL Technologies, Inc.)
### Schedule at a Glance

#### Monday, October 8

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM – 5:00 PM</td>
<td>Accreditation Inspector’s Training Workshop</td>
<td>Room 208</td>
</tr>
<tr>
<td>8:45 AM – 5:00 PM</td>
<td>User Group Meeting: GenDX</td>
<td>Room 203</td>
</tr>
<tr>
<td>Noon – 7:00 PM</td>
<td>Registration Open</td>
<td>Exhibit Hall C Foyer</td>
</tr>
<tr>
<td>5:30 PM – 7:00 PM</td>
<td>Accreditation &amp; Proficiency Testing Update</td>
<td>Ballroom A</td>
</tr>
<tr>
<td>7:00 PM – 8:00 PM</td>
<td>Keynote Address</td>
<td>Ballroom A</td>
</tr>
<tr>
<td>8:00 PM – 9:00 PM</td>
<td>Welcome Reception</td>
<td>Ballroom A &amp; B Foyer</td>
</tr>
</tbody>
</table>

#### Tuesday, October 9

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM – 4:00 PM</td>
<td>Registration Open</td>
<td>Exhibit Hall C Foyer</td>
</tr>
<tr>
<td>8:15 AM – 10:00 AM</td>
<td>Introduction to the Day: Antibodies and B Cells</td>
<td>Ballroom A</td>
</tr>
<tr>
<td></td>
<td>Thalachallour Mohanakumar, PhD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Plenary I: To B or Not To B</td>
<td>Ballroom A</td>
</tr>
<tr>
<td></td>
<td><strong>Moderators</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thalachallour Mohanakumar, PhD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Todd Eagar, PhD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Regulatory B Cells (Bio Cells) in Health and Disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thomas F. Tedder, PhD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Targeting BLyS Ligands and Receptors</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Michael P. Cancro, PhD</td>
<td></td>
</tr>
</tbody>
</table>
Schedule at a Glance (continued)

10:00 AM – 10:30 AM

AM Refreshment Break
Exhibit Hall C

10:30 AM – Noon

Symposium I: Transplantation, From Pillar to Post
Ballroom A

**Moderators**
Geoffrey Land, PhD, HCLD
Phillip Ruiz, MD, PhD

**Tools**
Geoffrey Land, PhD, HCLD

B Cell Tolerance in Organ Transplantation
Ali Naji, MD, PhD

Serology Complements Histology: C4d, C1q, and Morphology in the Diagnosis of Humoral Rejection
Evan A. Farkash, MD

Noon – 2:00 PM

User Group Luncheons:
SystemLink, Inc.: HistoTrac User’s Group
Room 209 AB

STEMCELL Technologies, Inc.: Purity Assessment for Chimerism Analysis
Room 203

Olerup, Inc.: HLA Typing with Olerup
Room 202

Olink Biosciences, Inc.: Linkage Biosciences Real-Time PCR HLA Workshop
Room 201

2:00 PM – 3:30 PM

Workshop 1: Case Studies in Solid Organ Transplantation
Room 104

**Moderator**
Christine Yamniuk, BS, BA

Workshop 2: The ASHI & AABB Joint Symposium
Room 102

Carol Panceoska, PhD, D(ABHI)
Patricia Kopko, MD
Paul Warner, PhD
Schedule at a Glance (continued)

Abstract Session 1: HLA Diversity
Room 101

Moderator
Henry Erlich, PhD

Abstract Session 2: Evolving Technologies
Room 103

Moderator
Dimitri Monos, PhD

3:30 PM – 4:00 PM
PM Refreshment Break
Exhibit Hall C

4:00 PM – 5:30 PM
Workshop 3: Harmonization of MFI’s (Internal & How the Physicians Use this Information)
Ballroom A

Michael Gautreaux, PhD, D(ABHI)
John Schmitz, PhD, D(ABMLI, ABHI)
Brett Loehmann, CHT, CHS

5:30 PM – 7:00 PM
Poster Session & Reception
Exhibit Hall C

7:00 PM – Midnight
User Group Dinner: Abbott Molecular Scientific Meeting
Room 202

7:30 PM – 9:30 PM
ASHI/ARB Inspectors’ & International Reception
Room 203

Wednesday October 10

7:30 AM – 6:00 PM
Registration Open
Exhibit Hall C Foyer

8:15 AM – 10:00 AM
Introduction to the Day: Clinical Biomarkers
Ballroom A

Peter Nickerson, MD, FRCPC

Plenary II: High Throughput Testing
Ballroom A

Moderators
Peter Nickerson, MD, FRCPC
Elaine Reed, PhD, D(ABHI)
Schedule at a Glance (continued)

High Dimensional Statistical Analysis of HLA Sequence Feature Associations
Richard Scheuermann, PhD

NCBI Bioinformatic Tools for Integration of MHC and Whole Genome Analyses: Current and Future
Michael Feolo, MS

10:00 AM - 10:30 AM
AM Refreshment Break
Exhibit Hall C

10:30 AM – Noon
Symposium II: Applications of Biomarkers in Transplantation
Ballroom A

Moderators
Elizabeth Trachtenberg, MS, PhD, D(ABHI)
Henry Erlich, PhD

The Discovery, Validation and Implementation of Biomarkers in Transplantation
Daniel R. Salomon, MD

Genetic Modulators of MHC Gene Expression
Julian Knight, PhD

The ABCs of HLA and HIV
Steven Wolinsky, MD

Noon – 2:00 PM
User Group Luncheons:
One Lambda: One Lambda Technical Luncheon
Ballroom B

2:00 PM – 3:30 PM
Workshop 4: Case Studies in Stem Cell Transplantation
Room 104

Moderator
Paula Arnold, PhD

Workshop 5: HLA Epitopes in Clinical Histocompatibility Testing
Room 102

Marcelo Fernández-Viña, PhD, D(ABHI)
Anat Tambur, DMD, PhD, D(ABHI)

Clinical Relevance of HLA Epitope Antigenicity and Immunogenicity
Rene Duquesnoy, PhD
Schedule at a Glance (continued)

Abstract Session 3: Clinical Metrics for Pre-Transplant Solid Organ Testing  
Room 101

**Moderator**  
William Hildebrand, PhD, D(ABHI)

Abstract Session 4: Best of the Rest  
Room 103

**Moderator**  
James Mathew, PhD

3:30 PM – 4:00 pm  
**PM Refreshment Break**  
Exhibit Hall C

4:00 PM – 5:30 PM  
**International Workshop Update**  
Room 104

Derek Middleton, DSc, PhD, FRC, PATH

Abstract Session 5: Clinical Relevance of Post-Transplant Antibodies  
Room 102

**Moderator**  
Peter Stastny, MD

Abstract Session 6: Immunomodulation  
Room 101

**Moderator**  
Elizabeth Trachtenberg, MS, PhD, D(ABHI)

5:45 PM – 6:45 PM  
**Joint Directors’ & Technologists’ Forum**  
Ballroom A

**iQCP: The Next Step in Quality**  
John A. Gerlach, PhD, D(ABHI)

**CPT Update**  
Sandra Helman, PhD

6:45 PM – 7:30 PM  
**Directors’ Forum**  
Room 101

**Technologists’ Forum**  
Room 102
Schedule at a Glance (continued)

Thursday, October 11

7:00 AM – 8:00 AM  Vendor Meeting  
Room 203

8:00 AM – 6:00 PM  Registration Open  
Exhibit Hall C Foyer

8:30 AM – 10:00 AM  Plenary III: Scientific Award Lectures  
Ballroom A

  Rose Payne Award  
Elaine F. Reed, PhD, D(ABHI)

  Paul Terasaki Award  
Defining the Immunological Risk Pre-Transplant  
Denis Glotz, PhD

  Distinguished Scientist Award  
Rene Duquesnoy, PhD

10:00 AM – 10:30 AM  AM Refreshment Break  
Exhibit Hall C

10:30 AM – Noon  Symposium III: Awards & Business Meeting  
Ballroom A

2:00 PM – 3:30 PM  Workshop 6: Crossmatching: Teaching an Old Dog New Tricks  
Ballroom A

  Nancy Higgins, MT, CHS  
Malek Kamoun, MD, PhD  
Todd Eagar, PhD

3:30 PM – 4:00 PM  Special Abstract Session: Scholar Awards  
Room 104

4:00 PM – 5:30 PM  PM Refreshment Break  
Ballroom AB Foyer

4:00 PM – 5:30 PM  KPD Workshop  
Ballroom A

  Annette Jackson, PhD  
Suzanne McGuire, RN, BSN, CCTC  
Jeffrey Veale, MD

7:00 PM – 11:00 PM  A Puerto Rican Carnival  
Terrace - Puerto Rico Convention Center  
Ticketed Event
Schedule at a Glance (continued)

Friday, October 12

8:00 AM – 10:30 AM
Registration Open
Exhibit Hall C Foyer

8:30 AM – 10:00 AM
Plenary IV: State of the Art of HSCT: Transplants from Haplo-Identical Donors
Ballroom A

Moderators
Marcelo Fernández-Viña, PhD, D(ABHI)
Chantale Lacelle, PhD

Utilizing Cord Blood Units
Mary Eapen, MD, MS

Transplants From HLA-Haploidentical Donors
Ephraim Fuchs, MD

Umbilical Cord Blood Banking & Transplantation
Joanne Kurtzberg, MD

10:00 AM – 10:30 AM
AM Refreshment Break
Ballroom AB Foyer

10:30 AM – Noon
Great Debate: Past, Present and Future of Ambiguities
Ballroom A

Moderator
John A. Gerlach, PhD, D(ABHI)

Dennis L. Confer, MD
Marilyn Pollack, PhD, D(ABHI)
Marcelo Fernández-Viña, PhD, D(ABHI)
Abstracts

Tuesday, October 9, 2012
2:00 PM - 3:30 PM

Workshop 1: Case Studies in Solid Organ Transplantation

1-OR
HLA-Bw4 REACTIVE ANTIBODIES IN PATIENTS WITH Bw4 POSITIVE PHENOTYPES.
Zhimin Xiang, Julie A. Houp, Annette M. Jackson. Medicine, The Johns Hopkins University, Baltimore, MD, USA.

2-OR
CASE STUDY: WHEN THE VIRTUAL AND ACTUAL CROSSTMATCH ARE DISCORDANT.
Jessica L. Jackstadt1, Donald M. Constantino1, Maryanne Mackay1, Laurel Gokee1, Jennifer Nielsen1, Kari Roberts1, Robert Jordan1, Peter Jindra1, David J. Conti2, Amy B. Hahn1. 1Transplantation Immunology Laboratory, Albany Medical College, Albany, NY, USA; 2Section of Transplantation, Division of General Surgery, Dept. of Surgery, Albany Medical College, Albany, NY, USA.

3-OR
DIFFERENCES BETWEEN LUMINEX REACTIVITY PATTERNS OF CLASS I EPITOPE-SPECIFIC ANTIBODIES: POSSIBLE EFFECT OF PEPTIDES IN THE GROOVE.
Rene J. Duquesnoy1, Marilyn Marrari1, Arend Mulder2, Frans Claas2. 1Division of Transplant Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 2Immunohematology, Leiden University Medical Center, Leiden, Netherlands.

4-OR
THE SIGNIFICANCE OF HLA-DPB1 TYPING IN RENAL TRANSPLANT PATIENTS AND IN HIGHLY SENSITIZED TRANSPLANT CANDIDATES.
Elizabeth A. Portwood1, Paul A. Brailey1, Alin L. Girnita1, Steve E. Woodle2. 1Transplantation Immunology, University of Cincinnati, Hoxworth Blood Center, Cincinnati, OH, USA; 2Department of Surgery, University of Cincinnati, Cincinnati, OH, USA.

5-OR
PROBLEM CASES IN PREDICTION OF CROSS MATCH (XM) OUTCOME FROM SINGLE ANTIGEN BEADS TESTS: NEGATIVE CDCXMs WITH A HIGH LEVEL OF DONOR SPECIFIC ANTIBODIES IN SAB ASSAYS.
David Hochman1, Ballabh Das1, Andrew D’Onofrio1, Louise Bergamini1, Allen J. Norin1,2. 1Transplant Immunology & Immunogenetics Laboratory, SUNY Downstate Medical Center, Brooklyn, NY, USA; 2Medicine, SUNY Downstate Medical Center, Brooklyn, NY, USA.
Norin: Gen-Probe: Speakers Bureau.

6-OR
MULTIPLE TEST METHODS FOR PROGNOSTIC IDENTIFICATION OF CLINICALLY-SIGNIFICANT ANTI-HLA ANTIBODIES.
Patricia A. Willey1, Donna Phelan1, Gerald Morris2, T. Mohanakumar1,3. 1HLA Laboratory, Barnes-Jewish Hospital, St. Louis, MO, USA; 2Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA; 3Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Abstracts

7-OR
TRANSMISSION OF MATERNAL ANTIBODY TOWARD HLA ANTIGEN OF A NEWBORN WITH FETAL CARDIOMYOPATHY.
Dong-Feng Chen1, Wendy Wegner1, Linda Peel1, Michael P. Carboni2. 1Department of Pathology and Clinical Laboratories, Duke University Medical Center, Durham, NC, USA; 2Pediatric Cardiology, Duke Children’s Hospital, Durham, NC, USA.

Tuesday, October 9, 2012
2:00 PM - 3:30 PM
Abstract Session 1: HLA Diversity

8-OR
TOOLS FOR IMPLEMENTATION OF SILVER STANDARD PRINCIPLES FOR HLA TYING.
Bob Milius1, Joel Schneider1, Michael Heuer1, Pradeep Bashyal1, Mike George1, Doug Schneyman1, Jane Pollack1, Abeer Madbouly1, Loren Gragert1, Jill Hollenbach1,2, Steven J. Mack2, Jack Bakker3, Werner Bochtler4, James Robinson5, Carlheinz Müller5, Martin Maiers1. 1Bioinformatics Research, National Marrow Donor Program, Minneapolis, MN, USA; 2Children’s Hospital Oakland Research Institute, Oakland, CA, USA; 3Europdonor Foundation, Leiden, Netherlands; 4Zentrale Knochenmarkspender-Register, Ulm, Germany; 5Anthony Nolan Research Institute, London, United Kingdom.

9-OR
GENERATION OF HLA DIVERSITY IN VITRO.
Shana L. McDevitt, Steven J. Mack, Kevin S. Williamson, Janelle A. Noble. Research, Children’s Hospital Oakland Research Institute, Oakland, CA, USA.

10-OR
SSO TO RESOLVE AMBIGUITIES CONSISTING OF TWO OR MORE ANTIGEN GROUPS IN ONE-PASS THRU SEQUENCING.
Carly Masaberg, Yi Xiao, Bin Tu, Kanthi Kariyawasam, Jennifer Ng, Carolyn Hurley. C.W. Bill Young DoD Marrow Program, Georgetown University, Rockville, MD, USA.

11-OR
VERY HIGH RESOLUTION HLA GENOTYPING WITH THE 454 LIFE SCIENCES GS FLX SYSTEM: SIMPLIFICATION OF WORKFLOW USING FUSION PRIMERS OR A FOUR PRIMER SYSTEM.
Cherie L. Holcomb1, Bryan Hoglund1, Timothy Williams2, Damian Goodridge3, Henry A. Erlich1. 1Human Genetics, Roche Molecular Systems, Inc., Pleasanton, CA, USA; 2Children’s Hospital and Research Center, Oakland, CA, USA; 3Conexio Genomics, Perth, Australia.
Abstracts

**12-OR**

**IN VITRO GENERATED PCR CROSSOVER PRODUCTS IDENTIFIED BY NEXT GENERATION SEQUENCING CORRESPOND TO SOME ALLELES IN THE IMGT DATABASE.**
Melinda V. Rastrou1, Cherie L. Holcomb1, Tim C. Williams2, Damian Goodridge3, Ana M. Lazaro4, Marcel Tilanus5, Henry A. Erlich1. 1Research Human Genetics, Roche Molecular Systems, Inc., Pleasanton, CA, USA; 2Research, Children’s Hospital and Research Center, Oakland, CA, USA; 3Programming, Conexio Genomics, Perth, Australia; 4C. W. Bill Young/Department of Defense, Georgetown University, Washington, DC, USA; 5Transplantation Immunology, Tissue Typing Laboratory, Maastricht University Medical Center, Maastricht, Netherlands.

**13-OR**

**MONOCLONAL ANTI-HLA-B27 CROSS REACTIVITY WITH OTHER HLA-B ANTIGENS.**
Laurie L. Voit, Lisa M. Hallaway, Manish J. Gandhi. Division of Transfusion Medicine, Mayo Clinic, Rochester, MN, USA.

**14-OR**

**HLA REGION AND LUNG CANCER SUSCEPTIBILITY: CONFIRMATION OF BAT3/BAG6 ASSOCIATION AND FUNCTIONAL REPLICATION.**

**Tuesday, October 9, 2012**

**2:00 PM - 3:30 PM**

**Abstract Session 2: Evolving Technologies**

**15-OR**

**REACTIVITY OF HLA EPI TOPE-SPECIFIC ANTIBODIES IN IG-BINDING, C1Q-BINDING AND LYMPHOCYTOTOXICITY ASSAYS.**
Rene J. Duquesnoy1, Marilyn Marrari1, Arend Mulder2, Frans Claas2. 1Division of Transplant Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 2Immunohematology, Leiden University Medical Center, Leiden, Netherlands.

**16-OR**

**SPECIFIC DEPLETION OF ANTI HLA-DR ANTIBODIES FROM LITER VOLUMES OF SENSITIZED PATIENT PLASMA.**
Curtis P. McMurtrey1, David Lowe2, Rico Buchli3, Rod VanGundy3, Sunil Daga2, David Briggs4, Daniel Zehnder2, Robert Higgins2, William Hildebrand1. 1Microbiology and Immunology, University of Oklahoma Health Science Center, Oklahoma City, OK, USA; 2Warwick Medical School, University of Warwick, Coventry, United Kingdom; 3Research, Pure Protein LLC, Oklahoma City, OK, USA; 4Histocompatibility and Immunogenetics, NHSBT Birmingham, Birmingham, United Kingdom; 5Renal & Transplantation, University Hospitals Coventry and Warwickshire, Coventry, United Kingdom.
Abstracts

17-OR
MODULATION OF microRNA-449a BY HEPATITIS C VIRUS (HCV) IN REGULATING EXPRESSION OF THE INFLAMMATORY BIOMARKER YKL40 THROUGH TARGETING COMPONENTS OF THE NOTCH/ NF KAPPA B SIGNALING PATHWAYS.
Nayan J. Sarma, Venkataswarup Tiriveedhi, Vijay Subramanian, Surendra Shenoy, Jeff Crippin, William Chapman, Thalachallour Mohanakumar. Surgery, Washington University School of Medicine, Saint Louis, MO, USA.

18-OR
QUANTITATIVE PCR FOR KILLER-CELL IMMUNOGLOBULIN-LIKE RECEPTORS (KIRS) RESEARCH GENOTYPING.

19-OR
TOWARDS ALLELE LEVEL HLA GENOTYPING: A COMPARISON OF NEXT-GENERATION SEQUENCING PLATFORMS – ION TORRENT PGM AND ILLUMINA MiSeq.
Curt Lind1, Kate Mackiewicz1, Jamie Duke1, Ariella Sasson2, Stephen Mahoney3, Eric Rappaport3, Olga Derbeneva1, Doug Wallace1,4, Erik Rozemuller5, Maarten Penning5, Wietse Mulder5, Dimitri Monos1,4. 1Department of Pathology and Laboratory Medicine, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA; 2Bioinformatics Core, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA; 3Nucleic Acid/PCR Core, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA; 4Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, USA; 5GenDx, Utrecht, Netherlands. Rozemuller: GenDx: Employee. Penning: GenDx: Employee. Mulder: GenDx: Employee.

20-OR
A DISTINCT REGULATORY IMMUNOPHENOTYPE DIFFERENTIATES TOLERANT AND NON-TOLERANT PEDIATRIC LIVER TRANSPLANT RECIPIENTS.
Laura J. Wozniak1, Yael D. Korin2, Giovanni Lopez2, Tiffany Smith2, Sue V. McDiarmid1, Elaine F. Reed2. 1Pediatric Gastroenterology, UCLA Mattel Children’s Hospital, Los Angeles, CA, USA; 2Pathology and Laboratory Medicine, UCLA Immunogenetics Center, Los Angeles, CA, USA.

21-OR
SOLUBLE HLA – A NEW GENERATION OF SINGLE ANTIGEN ASSAYS.
Rodney S. VanGundy1, Rebecca D. McAdams1, Kayla M. Lira1, Michael C. Eades1, Steven J. Cate2, Curtis P. McMurtry2, Steffan D. Sigler1, Aaron D. Rennels1, William H. Hildebrand2, Rico Buchli1. 1R&D, Pure Protein LLC, Oklahoma City, OK, USA; 2Microbiology and Immunology, Oklahoma University Health Sciences Center, Oklahoma City, OK, USA.
Abstracts

Wednesday, October 10, 2012
2:00 PM - 3:30 PM
Workshop 4: Case Studies in Stem Cell Transplantation

22-OR
CASE STUDY: AN UNPRECEDENTED FINDING OF LONG-TERM STABLE PERSISTENCE OF CD3+ LINEAGE CELLS FROM A FIRST TRANSPLANT MATCHED-SIB DONOR IN AN ALL PATIENT FOLLOWING A SECOND URD DOUBLE-CORD TRANSPLANT.
Paula J. Peterson1, Filippo Milano2, Colleen Delaney1,3, Shalini E. Pereira1,2,3. 1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 2Department of Laboratory Medicine, University of Washington, Seattle, WA, USA; 3825 Eastlake Ave. E, Seattle Cancer Care Alliance, Seattle, WA, USA.

23-OR
THE SEARCH FOR A MISSING HLA-DRB1*09 ALLELE.
Kimberley D. House, Grace A. Hommel-Berrey, Kathleen A. Backfish, Terry S. Arnoff, Andrew L. Lobashansky. Department of Medicine HLA Laboratory, Indiana University, Indianapolis, IN, USA.

24-OR
DISCREPANT A-LOCUS HLA TYPING RESULTS BETWEEN TESTING METHODOLOGIES: A CASE STUDY.
Carrera Kostur, Luz Stamm, Hamid Liacini, Noureddine Berka. Tissue Typing, Calgary Lab Services, Calgary, AB, Canada.

25-OR
LOSS OF HETEROZYGOSITY IN PATIENT WITH ACUTE MYELOCYTIC LEUKEMIA (AML).
Afzal Nikaein1, Jeffrey Kirkland1, Terry Knudsen1, Joona Robinson1, Vikas Bhushan2. 1Transplant Immunology, Texas Medical Specialty, Inc., Dallas, TX, USA; 2Stem Cell Transplant, Medical City Dallas Hospital, Dallas, TX, USA.

26-OR
GENOMIC ALTERATION CODING A NOVEL HLA-DQB1 ALLELE IDENTIFIED IN THE FAMILY OF A PATIENT WITH HEMATOLOGICAL MALIGNANCY.
Angelica DeOliveira, Runying Tian, Candace Young, Jennifer Deitz, Wendy Wegner, Gansuvd Balgansuren, Dong-Feng Chen. Pathology, Duke University Medical Center, Durham, NC, USA.

27-OR
HISTORY OF HLA-DP ANTIBODIES IN A POTENTIAL BONE MARROW RECIPIENT AFTER GRANULOCYTE TRANSFUSION: CLINICAL CONUNDRUM TO TRANSPLANT.
Manish J. Gandhi1, Laurie Voit1, Steven R. DeGoey1, Cynthia Kroning1, Mark A. Litzow2, Dennis Gastineau2, William Hogan2, Mrinal Patnaik2. 1Division of Transfusion Medicine, Mayo Clinic, Rochester, MN, USA; 2Division of Hematology, Mayo Clinic, Rochester, MN, USA.

28-OR
ALLELE SPECIFIC ANTI-HLA ANTIBODY IN A BONE MARROW TRANSPLANT PATIENT.
Ketevan Gendzekhadze, Laima Gaidulis, David Senitzer. HLA, City of Hope, Duarte, CA, USA.
Wednesday, October 10, 2012
2:00 PM - 3:30 PM
Abstract Session 3: Clinical Metrics for
Pre-Transplant Solid Organ Testing

29-OR
VALIDATION OF THE LUMINEX PLATFORM TO DETECT HLA ANTIBODIES: EFFECT OF STANDARDIZING OPERATION PROCEDURES ON TEST VARIABILITY BY CTOT CORE LABORATORIES.
Ping Rao1, Zilu Zhang1, Howard Gebel2, Robert A. Bray3, Indira Guleria4, Thalachallour Mohanakumar4, Peter Nickerson5, Anat Tambur6, Adriana Zeevi7, Peter Heeger8, David Gjertson1, Elaine Reed1. 1Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA, USA; 2Department of Pathology, Emory University Hospital, Atlanta, GA, USA; 3Transplantation Research Center, Harvard Medical School, Boston, MA, USA; 4Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA; 5Section of Nephrology, University of Manitoba, Winnipeg, MB, Canada; 6Transplant Immunology Laboratory, Northwestern University, Chicago, IL, USA; 7Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 8Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA.

30-OR
CANADA-WIDE EVALUATION OF RAPID OPTIMIZED FLOW CROSSMATCH (ROFCXM) PROTOCOL.
Robert Liwski1, Denise Pochinco2, Kathryn Tinckam3, Howard Gebel4, Patricia Campbell5, Peter Nickerson6,7. 1Department of Pathology, Dalhousie University, Halifax, NS, Canada; 2Transplantation Immunology, Diagnostic Services of Manitoba, Winnipeg, MB, Canada; 3Laboratory Medicine Program, University of Toronto, Toronto, ON, Canada; 4Department of Pathology, Emory University Hospital, Atlanta, GA, USA; 5Departments of Medicine and Laboratory Medicine, University of Alberta, Edmonton, AB, Canada; 6Organ and Tissue Donation and Transplantation, Canadian Blood Services, Winnipeg, MB, Canada; 7Department of Medicine, University of Manitoba, Winnipeg, MB, Canada.

31-OR
THE INFLUENCE OF ANTI-HLA ANTIBODY CONCENTRATION AND ISOTYPES ON SAB MFI.
Steven Cate1, Curtis P. McMurtrey1, Ken Jackson1, David Lowe2, Rico Buchli3, Rod VanGundy2, Sean Osborn1, Alexandar Mojsilovic1, Daniel Zehnder2, William Hildebrand1. 1Microbiology and Immunology, University of Oklahoma Health Science Center, Oklahoma City, OK, USA; 2Warwick Medical School, University of Warwick, Coventry, United Kingdom; 3Research, Pure Protein LLC, Oklahoma City, OK, USA.
Abstracts

32-OR
ARE ALL ANTI-HLA-Cw ANTIBODIES DETECTED WITH LUMINEX SINGLE ANTIGEN BEAD REAL ANTIBODIES?
Qingyong Xu1,2, Twyla Pearce2, Elly Johnson2, Donna Rich-Sperling3, Karey Gorkoff2, Terry Akister2, Jianping Li3. 1Pathology & Lab Medicine, University of Saskatchewan, Saskatoon, Canada; 2Lab Medicine, St. Paul’s Hospital, Saskatoon, Canada; 3Pathology & Lab Medicine, The Ottawa Hospital, Ottawa, Canada.

33-OR
GOING WITH THE FLOW, CANADIAN CROSSMATCH STANDARDIZATION.
Robert S. Liwski1, Denise Pochinco2, Kathryn Tinckam3, Patricia Campbell4, Peter Nickerson5,6. 1Department of Pathology, Dalhousie University, Halifax, Canada; 2Transplantation Immunology, Diagnostic Services of Manitoba, Winnipeg, Canada; 3Laboratory Medicine Program, University of Toronto, Toronto, Canada; 4Department of Medicine and Laboratory Medicine, University of Alberta, Edmonton, Canada; 5Organ and Tissue Donation and Transplantation, Canadian Blood Services, Winnipeg, Canada; 6Department of Medicine, University of Manitoba, Winnipeg, Canada.

34-OR
PROFILING PURIFIED HLA-DR SPECIFIC ANTIBODIES.
Curtis P. McMurtrey1, David Lowe2, Rico Buchli3, Steven Cate1, Sean Osborn1, Rod VanGundy3, Sunil Daga4, Wilfried Bardet5, Alexandar Mojsilovic5, David Briggs6, Daniel Zehnder2, Robert Higgins5, William Hildebrand1. 1Microbiology and Immunology, University of Oklahoma Health Science Center, Oklahoma City, OK, USA; 2Warwick Medical School, University of Warwick, Coventry, United Kingdom; 3Research, Pure Protein LLC, Oklahoma City, OK, United Kingdom; 4Histocompatibility and Immunogenetics, NHSBT Birmingham, Birmingham, United Kingdom; 5Renal & Transplantation, University Hospitals Coventry and Warwickshire, Coventry, United Kingdom.


35-OR
HIGH TITER HLA ANTIBODY IS C1q BINDING AND ASSOCIATED WITH INCREASED RISK OF ANTIBODY MEDIATED REJECTION IN HEART ALLOGRAFT RECIPIENTS.
John G. Lunz1, Brian Feingold2, Steven Webber2, Larry Jelinek1, Michael Shullo4, Jeffery Teuteberg1, Christian Bermudez3, Adriana Zeevi1. 1Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA; 2Medicine, Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, USA; 3Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA; 4Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Abstracts

**Wednesday, October 10, 2012**

**2:00 PM - 3:30 PM**

**Abstract Session 4: Best of the Rest**

### 36-OR

**PEPTIDE LIGANDS PRESENTED BY NON-PROGRESSOR-ASSOCIATED HLA B*57:01 FOLLOWING HIV-1 INFECTION.**

Jane C. Yaciuk, Stephen R. Vernon, Wilfried Bardet, Fredda Schafer, Matthew S. Skaley, Danijela Mojsilovic, Aleksandar Mojsilovic, Kenneth W. Jackson, William H. Hildebrand. Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

### 37-OR

**CLASS I MHC BINDING MOTIFS FROM CYNOMOLGUS AND RHESUS MACAQUES.**

Danijela Mojsilovic¹, Kenneth W. Jackson¹, Wilfried Bardet¹, Fredda Schafer¹, Aleksandar Mojsilovic¹, Sean Osborn¹, David Watkins², David O’Connor³, William H. Hildebrand¹. ¹Department of Microbiology and Immunology, University of Oklahoma Health Science Center, Oklahoma City, OK, USA; ²Department of Pathology, University of Miami Miller School of Medicine, Miami, FL, USA; ³Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, USA.

### 38-OR

**ACTIVATING KIR GENE PROFILE OF RENAL TRANSPLANT RECIPIENTS CONFERS PROTECTION AGAINST CMV INFECTION.**

Poonam Dharmani¹², Rehan M. Faridi¹², Abdelhamid Liacini¹³, Jagdeep Doulla³, Aylin Sar⁴, Serdar Yilmaz⁴, Noureddine Berka¹³, Faisal Khan¹²³. ¹Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Canada; ²Paediatrics, University of Calgary, Calgary, Canada; ³Tissue Typing Laboratory, Calgary Laboratory Services, Calgary, Canada; ⁴Transplantation, University of Calgary, Calgary, Canada.

### 39-OR

**CYTOKINE AND CHEMOKINE GENE POLYMORPHISMS IMPACT ON CMV INFECTION IN LUNG TRANSPLANT RECIPIENTS.**

Adriana Zeevi, Hong Nguyen, Maria Brooks, Kathy Spichy, Diana Zaldonis, Robert Ferrell, Fernanda Silveira, Joseph Pilewski, Maria Crespo, Jay Bhamia, Christian Bermudez, Cornelius Clancy. Pathology, University of Pittsburgh, Pittsburgh, PA, USA.

### 40-OR

**DIFFERENTIAL DOSE-DEPENDENT EFFECTS OF BELATACEPT AND MYCOPHENOLIC ACID ON REGULATORY T CELL GENERATION IN MLR.**

James M. Mathew, Joshua Miller, Xuemei Huang, Dhivya Chandrasekaran, Li Chen, Josh Levitsky. Surgery - Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Mathew: Bristol-Myers-Squibb: Grant Research. Miller: Bristol-Myers-Squibb: Grant Research. Levitsky: Bristol-Myers-Squibb: Grant Research.
Abstracts

41-OR
SECOND GENERATION GSSP’s FOR HLA CLASS 1 AND CLASS 2 ACCELERATE HIGH-RESOLUTION HLA TYPINGS.

42-OR
ASSIGN-A+1.5: A SEQUENCE ANALYSIS SOFTWARE THAT SIMPLIFIES THE HIGH THROUGHPUT DETECTION OF GENETIC VARIANTS.

Wednesday, October 10, 2012
4:00 PM - 5:30 PM
Abstract Session 5: Clinical Relevance of Post-Transplant Antibodies

43-OR
THE INCIDENCE OF CLASS II DSA DEPENDS ON THE TYPE OF MISMATCH AND VARIES WITH CALCINEURIN INHIBITOR DRUG LEVELS.
Luis G. Hidalgo1, Donald Legatt2, Monika Oliver2, Patricia M. Campbell1. 1Lab. Medicine and Pathology, University of Alberta Hospital - HLA Laboratory, Edmonton, AB, Canada; 2Lab. Medicine and Pathology, University of Alberta, Edmonton, AB, Canada.
Campbell: Astellas: Science Med Advisor; Other: Currently involved as the central HLA laboratory for a clinical trial.

44-OR
HLA CLASS II (HLA II) LIGATION BY ANTIBODIES (Ab) INDUCES SIGNAL TRANSUDCTION AND CYTOSKELETON REORGANIZATION IN ENDOTHELIAL CELLS (EC).
Fang Li, Xiaohai Zhang, Elaine F. Reed. Pathology and Lab Medicine, Immunogenetics Center, University of California Los Angeles, Los Angeles, CA, USA.

45-OR
C1q-FIXING HLA ANTIBODIES AND KIDNEY TRANSPLANTATION.
Elvira Poggi1, Giuseppina Ozzella1, Daniela Caputo2, Rosa Cremona2, Cecilia Palombi2, Annarita Manfreda2, Domenico Adorno2, Antonina Piazza1. 1Institute of Translational Pharmacology Unit of Rome S. Camillo Hospital, National Council of Researches, Rome, Italy; 2Regional Transplant Center of Lazio, Tor Vergata University of Rome, Rome, Italy.
Abstracts

46-OR
RESULTS FROM THE CURRENT 16TH INTERNATIONAL HISTOCOMPATIBILITY AND IMMUNOGENETICS WORKSHOP STUDY ON NATURAL HISTORY OF POST-TRANSPLANT HLA ANTIBODY DEVELOPMENT.

Miyuki Ozawa1, Matthew Everly1, Paul I. Terasaki2. 1Research II, One Lambda, Inc., Los Angeles, USA; 2Terasaki Foundation Laboratory, Los Angeles, USA.


47-OR
RENAL SURVEILLANCE PROTOCOL BIOPSY WITH DONOR SPECIFIC ANTIBODY POST-TRANSPLANT.

Robert F. McAlack1, Alden Doyle1, Cheryl A. Hanau1, Suganthi Soundararajan1, Elizabeth Tecza2, Nathan Burvainis2, Amando Dalisay2, Allison Gasiewski2, Michael Panos2. 1Pathology, Drexel University College of Medicine, Philadelphia, PA, USA; 2Pathology, Hahnemann University Hospital, Tenet, Philadelphia, PA, USA.

48-OR
DE NOVO DEVELOPMENT OF IMMUNE RESPONSES TO DONOR HLA AND KIDNEY ASSOCIATED SELF ANTIGENS, FIBRONECTIN AND COLLAGEN IV (AUTOIMMUNITY) ARE ASSOCIATED WITH TRANSPLANT GLOMERULOPATHY FOLLOWING HUMAN KIDNEY TRANSPLANTATION.

Nataraju Angaswamy1, C. Klein1, D. Phelan1, J. Wellen1, S. Shenoy1, W. Chapman1, T. Mohanakumar1,2. 1Department of Surgery, Washington University School of Medicine, Saint Louis, MO, USA; 2Immunology and Pathology, Washington University School of Medicine, Saint Louis, USA.

49-OR
DETECTION OF ANTIBODIES AGAINST MICA ANTIGENS IN A COLLABORATION OF EIGHTEEN LABORATORIES.

Yizhou Zou, Peter Stastny. Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.

Wednesday, October 10, 2012
4:00 PM - 5:30 PM
Abstract Session 6: Immunomodulation

50-OR
POLYMORPHISMS ALTERING THE RESIDUE TRIAD 97/114/156 CONFER TAPASIN INDEPENDENCY TO HLA CLASS I MOLECULES.

Soumya Badrinath, Trevor Huyton, Rainer Blasczyk, Christina Bade-Doeding. Institute for Transfusion Medicine, Hannover Medical School, Hannover, Germany.
Abstracts

51-OR
RELATIONSHIP BETWEEN HLA RESTRICTED MINOR HISTOCOMPATIBILITY ANTIGENS AND GRAFT VERSUS HOST DISEASE IN PATIENTS FOLLOWING MATCHED UNRELATED PERIPHERAL BLOOD STEM CELL ALLOGRAFTS.
Christine A. Tremblay¹, Marcela R. Uribe¹, Daniel Peaceman², Rachel B. Salit², Steven Pavletic², Sharon D. Adams¹, Willy A. Flegel¹. ¹Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA; ²National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

52-OR
LIGATION OF HLA CLASS II MOLECULES ON ENDOTHELIAL CELLS STIMULATES mTORC1 SIGNALING AND CELL PROLIFERATION.
Yi-Ping Jin, Xiaohai Zhang, Sahar Salehi, Kathryn Zavala, Elaine F. Reed. Pathology and Laboratory Medicine, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, USA.

53-OR
IDENTIFICATION OF T-CELL LYMPHOMA LIPID LIGANDS BOUND BY CD1c.
Matthew Skaley¹, Daryl Cox¹, Wilfried Bardet¹, Curtis McMurtry¹, Ken Jackson¹, Steven Cate¹, Aleksander Mojsilovic¹, Jenny Gumperz², William Hildebrand¹. ¹Microbiology & Immunology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; ²Medical Microbiology and Immunology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.

54-OR
PUBLISHED HLA-DQA1 ASSOCIATIONS ON DRB1-DQB1 HAPLOTYPES PREDICT THE FLOW CYTOMETRY CROSSMATCH (FCXM) IN A RETRANSPANT KIDNEY RECIPIENT WITH DQA1 ANTIBODY: IMPLICATIONS FOR LISTING UNACCEPTABLE ANTIGENS.
Angelo N. Arnold¹,², Abdur Rahman¹, Maria Balazy¹, Alice Hochbaum¹, Marzanna Krolik¹, John T. Fallon¹,². ¹Transplant Immunogenetics Laboratory, Westchester Medical Center, Valhalla, NY, USA; ²Pathology, New York Medical College, Valhalla, NY, USA.

55-OR
RESTROSPECTIVE EVALUATION OF UNEXPECTED POSITIVE FLOW CYTOMETRIC CROSSMATCH RESULTS.
Liang Wan, Dong-Feng Chen. Department of Pathology and Clinical Laboratories, Duke University Medical Center, Durham, NC, USA.

56-OR
CONTRIBUTION OF KIR AND HLA GENETICS IN RENAL TRANSPLANTATION: MISMATCH BETWEEN KIR3DL2 LIGANDS IN RECIPIENT AND DONOR INFLUENCES ALLOGRAFT STABILITY AND REJECTION IN RENAL TRANSPLANT PATIENTS.
Elizabeth A. Trachtenberg¹, Jill A. Hollenbach¹, Franziska Cohen¹, Fernanda R. Goodridge¹, Martha Lader¹, Daniel Warren⁷, Henry A. Erlich¹,³, Daniel R. Salomon⁴. ¹Center of Genetics, Children’s Hospital Oakland Research Institute, Oakland, CA, USA; ²School of Medicine, Johns Hopkins University, Baltimore, MD, USA; ³Dept of Human Genetics, Roche Molecular Systems, Pleasanton, CA, USA; ⁴Dept of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA.
Abstracts

Thursday, October 11, 2012
2:00 PM - 3:30 PM
Special Abstract Session: Scholar Awards

57-OR
GAMMA-TYPE™: SIMPLE PCR-SSP’S TO ENABLE THE ASSESSMENT OF HAPLOTYPE MATCHING BETWEEN UNRELATED STEM CELL DONORS AND PATIENTS.

58-OR
IMMUNODOMINANT AND SUBDOMINANT WNV PEPTIDE HLA COMPLEXES ARE PRESENTED AT DIFFERENT LEVELS AND ARE TAP DEPENDENT.
Curtis P. McMurtrey1, Sojung Kim2, Rinki Jain4, Wilfried Bardet1, Fredda Schafer1, Michael S. Diamond3, Jon Weidanz4, Ted Hansen2, William Hildebrand1. 1Microbiology and Immunology, University of Oklahoma Health Science Center, Oklahoma City, OK, USA; 2Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA; 3Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO, USA; 4Center for Immunotherapeutic Research, Texas Tech University Health Sciences Center, Abilene, TX, USA.

59-OR
A WEBSITE-BASED INTERNATIONAL REGISTRY OF ANTIBODY-DEFINED HLA EPITOPES.
Marilyn Marrari1, Luiz Claudio D.M. Sousa2, Semiramis J.H. do Monte3, Adalberto S. da Silva3, Keylla Maria S.U. Aita4, Jose Renato P.M. Barroso4, Rene J. Duquesnoy1. 1Division of Transplant Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 2Informatics and Statistics, Federal University of Piaui, Teresina, PI, Brazil; 3Immunogenetics and Molecular Biology, Federal University of Piaui, Teresina, PI, Brazil; 4Distance Education Center, Federal University of Piaui, Teresina, PI, Brazil.

60-OR
IDENTIFICATION OF NOVEL MYCOBACTERIUM TUBERCULOSIS LIGANDS AND EPITOPES RESTRICTED BY HLA-A2.
Curtis P. McMurtrey1, Wilfried Bardet1, Fredda Schafer1, Meghan Liles1, Katelynne Toren2, Megan Null2, Gwendolyn Swarbrick2, Deborah Lewinsohn2, David Lewinsohn2, William Hildebrand1. 1Microbiology and Immunology, University of Oklahoma Health Science Center, Oklahoma City, OK, USA; 2Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, OR, USA.
Abstracts

Tuesday, October 9, 2012
5:30 PM - 7:00 PM
Poster Session

1-P
CAN WE ACCURATELY PREDICT CROSSMATCH OUTCOMES MEDIATED BY ANTI-DQA1 ANTIBODIES ASSIGNED BY SINGLE ANTIGEN BEAD ANALYSIS?
Nebila M. Abdulwahab, Adam Schoen, June Inlow, Aisha Eltayeb, Nicholas Dipaola. Clinical Histocompatibility Laboratory, The Ohio State University Wexner Medical Center, Columbus, OH, USA.

2-P
COMPLEMENTARY TESTING USING SOLID PHASE AND FLOW CYTOMETRY TECHNOLOGIES PROVIDES ACCURATE ASSESSMENT OF PREFORMED DSA.
Patrick W. Adams, Nicholas R. DiPaola, Matthew S. Kott, Ronald P. Pelletier. Tissue Typing, Ohio State University, Columbus, OH, USA.

3-P
VARIABILITY IN MFI VALUE FOR DIFFERENT HLA ANTIBODIES DUE TO TECHNICAL (TECHNOLOGIST TO TECHNOLOGIST) VARIATION OCCURS IN HIGHER PROPORTIONS FOR LOW STRENGTH ANTIBODIES.
Saber J. AlZahrani1, Ahmed S. AlOtaibi1, Dalal H. AlAbduladheem1, Kenana M. AlAjlan1, Faisal Khan2,3,4, Noureddine Berka2,3,4. 1Histocompatibility and Immunogenetics Laboratory, King Fahad Specialist Hospital-Dammam, Dammam, Saudi Arabia; 2Histocompatibility and Immunogenetics Laboratory, Calgary Laboratory Services, Calgary, AB, Canada; 3Departments of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada; 4Departments of Pathology and Laboratory Medicine and Paediatrics, University of Calgary, Calgary, AB, Canada.

4-P
CORRELATION BETWEEN ONE LAMBDA LAB TYPE HLA CLASS I TYPING VERSUS SEQUENCE BASED TYPING.
Moheeb Al-Awwami, Saher Sandoqa, Fadi Alzayer. Histocompatibility and Immunogenetics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

5-P
OPTIMIZATION OF THE POSITIVE CONTROL SERUM IN FLOW CYTOMETRY CROSSMATCH.
Fadi S. AlZayer, Arlene J. Santos, Mariam E. Garcia, Amal N. AlGharably, Moheeb A. Al-Awwami. pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Abstracts

6-P
VENTRICULAR ASSIST DEVICES (VAD) ARE HIGHLY SIGNIFICANTLY ASSOCIATED WITH CLASS I HLA ALLOSENSITIZATION.
Medhat Askar1, Eileen Hsich2, Patrick Reville1, Amy S. Nowacki1, Aiwen Zhang1, Lynne Klingman1, Suzanne Bakdash1, William Baldwin1, Nicholas Smedira1, David Taylor2, Randall Starling2, Gonzalo Gonzalez-Stawinski1. 1Allogen Laboratories, Cleveland Clinic, Cleveland, USA; 2Cardiovascular Medicine, Cleveland Clinic, Cleveland, USA; 3Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, USA; 4Clinical Pathology, Cleveland Clinic, Cleveland, USA; 5Immunology, Cleveland Clinic, Cleveland, USA; 6Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, USA; 7Thoracic and Cardiovascular Surgery, Baylor University Medical Center, Dallas, USA.

7-P
DERIVATION AND TESTING HLA MONOSPECIFIC ANTIBODIES – IDENTIFICATION OF AGREEABLE REAGENTS.
Kayla M. Lira1, Rebecca D. McAdams1, Rodney S. VanGundy1, Michael C. Eades1, Steffan D. Sigler1, Aaron D. Rennels1, William H. Hildebrand2, Rico Buchli1. 1R&D, Pure Protein LLC, Oklahoma City, OK, USA; 2Microbiology and Immunology, Oklahoma University Health Sciences Center, Oklahoma City, OK, USA.

8-P
FORCED DEGRADATION STUDIES – SOLUBLE HLA STRESS TESTING COMPROMISING THE INTEGRITY OF HLA PROTEINS ON SINGLE ANTIGEN BEADS.
Steffan D. Sigler1, Rebecca D. McAdams1, Kayla M. Lira1, Rodney S. VanGundy1, Michael C. Eades1, Aaron D. Rennels1, William H. Hildebrand2, Rico Buchli1. 1R&D, Pure Protein LLC, Oklahoma City, OK, USA; 2Microbiology and Immunology, Oklahoma University Health Sciences Center, Oklahoma City, OK, USA.

9-P
FACTORS THAT INFLUENCE CONSISTENCY IN HLA SINGLE ANTIGEN ASSAYS – A STUDY DISCUSSING FUTURE STANDARDIZATION STRATEGIES.
Rebecca D. McAdams1, Kayla M. Lira1, Rodney S. VanGundy1, Michael C. Eades1, Steffan D. Sigler1, Aaron D. Rennels1, William H. Hildebrand2, Rico Buchli1. 1R&D, Pure Protein LLC, Oklahoma City, OK, USA; 2Microbiology and Immunology, Oklahoma University Health Sciences Center, Oklahoma City, OK, USA.

10-P
DECONVOLUTION OF ANTI-HLA SERA USING SOLUBLE HLA-LINKED MATRICES.
Rodney S. VanGundy1, Michael C. Eades1, Rebecca D. McAdams1, Curtis P. McMurtrey2, Steven J. Cate2, Kayla M. Lira1, Steffan D. Sigler1, Aaron D. Rennels1, William H. Hildebrand2, Rico Buchli1. 1R&D, Pure Protein LLC, Oklahoma City, OK, USA; 2Microbiology and Immunology, Oklahoma University Health Sciences Center, Oklahoma City, OK, USA.

11-P
WILL THE TRUE DQ ANTIBODY PLEASE STEP FORWARD?
Angela D. Busacco, Danielle Meehan, Myra Coppage. Lab Medicine-HLA Lab, University of Rochester Medical Center, Rochester, NY, USA.
Abstracts

12-P
HLA ANTIBODY: WHAT IS UNACCEPTABLE?
Angela D. Busacco, Danielle Meehan, Myra Coppage. Lab Medicine-HLA Laboratory, University of Rochester Medical Center, Rochester, NY, USA.

13-P
INCREASED RENAL TRANSPLANTS FOR SENSITIZED RECIPIENTS FOLLOWING VIRTUAL CROSSMATCH INTRODUCTION: ONE CENTER’S EXPERIENCE.
Robert Cirocco, Jennifer Mendiolina, Lindsey Biondi, Michael Moritz. HLA Laboratory, Transplant Center, Lehigh Valley Health Network, Allentown, PA, USA.

14-P
THE COMPARISON OF SERUM VS EDTA-PLASMA WHEN PERFORMING SINGLE PHASE SINGLE ANTIGEN BEAD TESTING.
Steven R. DeGoey, Rachel E. Barnes, Crystal K. Keso, Lisa M. Hallaway, Manish J. Gandhi. Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

15-P
SIGNIFICANT INCREASE IN DECEASED DONOR KIDNEY TRANSPLANTS IN HIGHLY SENSITIZED PATIENTS BY IMPLEMENTING VIRTUAL CROSSMATCH: A UNICENTER EXPERIENCE.
Zeying Du1, Sangeeta Mehendale1, Bozena Labuda2, Andres Jaramillo1, Sujata Gaitonde1,2. 1Pathology, University of Illinois at Chicago, Chicago, IL, USA; 2Histocompatibility Laboratory, Gift of Hope Organ & Tissue Donor Network, Itasca, IL, USA.

16-P
ASSOCIATION OF HLA CLASS I SINGLE ANTIGEN BEAD ASSAY WITH T CELL FLOW CROSSMATCH REACTIVITY: THE EFFECT OF ANTIBODIES AGAINST SPLIT ANTIGEN PRODUCTS AND ALLELIC VARIANTS.
Lauren Dvorscak, Aaron Pritchard, Sara Koenig. Department of Pathology, University of New Mexico / Tricore Reference Laboratory, Albuquerque, NM, USA.

17-P
ANGIOTENSIN II TYPE 1 RECEPTOR SENSITIZATION IN LUNG TRANSPLANTATION.
Hooi Sian Eng1, George J. Arnaoutakis2, Donna Lucas1, Timothy J. George2, Claude A. Beatty2, Christian A. Merlo1,4, Mary S. Leffell1, Ashish S. Shah2, Andrea A. Zachary1. 1Immunogenetics Laboratory, Johns Hopkins University, Baltimore, MD, USA; 2Division of Cardiac Surgery, The Johns Hopkins Medical Institutions, Baltimore, MD, USA; 4Division of Pulmonary and Critical Care Medicine, The Johns Hopkins Medical Institutions, Baltimore, MD, USA; 4Bloomberg School of Public Health, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.

18-P
DETERMINATION OF DONOR SPECIFIC ANTIBODY BY LUMINEX SINGLE ANTIGEN ASSAY IN TURKISH RENAL TRANSPLANT CANDIDATES.
Sevim Gönen1, Sevcan Bakkaloglu Ezgü2, Galip Güz3. 1Faculty of Medicine Pediatric Nephrology, Gazi University, Ankara, Turkey; 2Faculty of Medicine Pediatric Nephrology, Gazi University, Ankara, Turkey; 3Faculty of Medicine Nephrology, Gazi University, Ankara, Turkey.
Abstracts

19-P
DP OR NOT DP? THAT IS THE QUESTION.
Sharlie B. Brown1, David F. Kiger1, Jeffrey Rogers2, Michael D. Gautreaux1. 1HLA/Immunogenetics Laboratory, Wake Forest School of Medicine, Winston-Salem, NC, USA; 2Abdominal Organ Transplant Program, Wake Forest School of Medicine, Winston-Salem, NC, USA.

20-P
BACK TO THE FUTURE: HEAT-TREATING FOR SOLID PHASE ANTIBODY TESTING.
Jennie W. Stewart, Elaine F. O’Shields, David F. Kiger, Michael D. Gautreaux. HLA/Immunogenetics Laboratory, Wake Forest School of Medicine, Winston-Salem, NC, USA.

21-P
CLINICAL RELEVANCE OF PREFORMED HLA DONOR SPECIFIC ANTIBODIES DETECTED BY SINGLE ANTIGEN LUMINEX ASSAY ON KIDNEY TRANSPLANTS PERFORMED WITH NEGATIVE COMPLEMENT DEPENDENT CYTOTOXICITY T AND B CROSSMATCHES.
Alexandre Holanda-Cavalcanti1,2,3, Érika F. Campos1,2, Patricia C. Grenzi1,2, Renato De Marco2, Gisele F. Rampim2, Helio Tedesco-Silva3, Jose O. Medina-Pestana1,3, Maria Gerbase-DeLima1,2. 1Escola Paulista Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil; 2Immunogenetics Institute, AFIP, São Paulo, SP, Brazil; 3Hospital do Rim e Hipertensão, Fundação Oswaldo Ramos, São Paulo, SP, Brazil.

22-P
IMPACT OF HLA MATCHING AND PRE-TRANSPLANT ANTI-HLA ANTIBODIES ON KIDNEY GRAFT SURVIVAL.
Maria Gerbase-DeLima1,3, Luiz A. Pereira2, Sonia Coria2. 1Immunogenetics Institute, AFIP, São Paulo, SP, Brazil; 2Servico Estadual de Transplantes, Secretaria da Saude, São Paulo, SP, Brazil; 3Universidade Federal de São Paulo, São Paulo, SP, Brazil.

23-P
HLA-Cw EXPRESSION AND CROSSMATCH CORRELATION.
Idoia Gimferrer1, Jill Leslie1, Jeffrey McCormack2. 1HLA laboratory, OU Medical Center, Oklahoma City, OK, USA; 2Pathology Department, OU Health Science, Oklahoma City, OK, USA.

24-P
DETERMINATION OF AN ANTIGEN DENSITY CORRECTION FACTOR FOR CLASS I AND II SINGLE ANTIGEN BEADS: USEFUL OR NOT?
Anne Halpin, Deanna Manna, Luis Hidalgo, Patricia Campbell. Histocompatibility Laboratory, University of Alberta Hospital, Edmonton, AB, Canada.

25-P
VARIABILITY IN HLA CLASS I AND HLA-DR SURFACE EXPRESSION ON MEMORY T AND B CELLS – DIFFICULT TO SEE WITH THE USE OF PRONASE.
Wilfred Lam, Luis G. Hidalgo, Anne Halpin, Patricia M. Campbell. Lab. Medicine and Pathology, Univ. of Alberta Hospital - HLA Laboratory, Edmonton, AB, Canada.
Abstracts

26-P
FALSE-POSITIVE FLOW CYTOMETRY CROSSMATCH RESULTS WITH PRONASE-TREATED T-CELLS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS.
Kristin Sieg, Daniel Magas, Katarzyna Brooks, Justin D. Carrera, Bozena Labuda, Martin D. Jendrisak, Andres Jaramillo. Histocompatibility Laboratory, Gift of Hope Organ & Tissue Donor Network, Itasca, IL, USA.

27-P
FLOW CYTOMETRY CROSSMATCH STANDARDIZATION IN LUNG TRANSPLANTATION: RESULTS FROM THE HLA ANTIBODIES AFTER LUNG TRANSPLANTATION (HALT) STUDY GROUP.
Dolly Tyan1, Medhat Askar2, Lee Ann Baxter-Lowe3, Thalachallour Mohanakumar4, Marilyn Pollack5, Malek Kamoun6. 1Pathology, Stanford University, Stanford, CA, USA; 2Allogeneic Laboratories, Cleveland Clinic Foundation, Cleveland, OH, USA; 3Surgery, UCSF, San Francisco, CA, USA; 4Surgery, Washington University in St. Louis, St. Louis, MO, USA; 5Pathology, University of Texas Health Science Center, San Antonio, TX, USA; 6Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.

28-P
EFFICIENT USE OF ONLINE PRE-SELECTED PAIRS FOLLOWED BY VIRTUAL CROSSMATCHING ENABLES TRANSPLANTS THROUGH MULTICENTER KIDNEY PAIRED DONATION (KPD).
Malek Kamoun1, Michael Cecka2, Lee Ann Baxter-Lowe3, Joe Sinacore5, Marc L. Melcher4. 1Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA; 2Pathology, UCLA, Los Angeles, CA, USA; 3Surgery, UCSF, San Francisco, CA, USA; 4Surgery, Stanford University, Palo Alto, CA, USA; 5Research & Education, National Kidney Registry, Babylon, NY, USA.
Sinacore: NKR: Employee.

29-P
FETAL BOVINE SERUM: THE PERFECT DILUENT.
Patrick Kennedy, Jean L. Heneghan, Karen A. Sullivan. Histocompatibility & Immunogenetics Lab, Tulane University Medical Center, New Orleans, LA, USA.

30-P
C1q POSITIVE DSA EXPLAINS CONFLICTING RESULT OF POSITIVE CROSSMATCH IN LIVER TRANSPLANTATION.
Taba Kheradmand1, Rebecca Upchurch1, Walter Herczyk1, John Hart1, John Renz2, Helen Te2, Susan R. Marino1,2. 1Pathology, University of Chicago Medicine, Chicago, IL, USA; 2Surgery, University of Chicago Medicine, Chicago, IL, USA.

31-P
NOVEL PREEMPTIVE PROTOCOL IMPROVES GRAFT SURVIVAL AMONG SENSITIZED RENAL TRANSPLANT PATIENTS.
Pam Kimball, Amit Sharma, Dhiren Kumar, Anne King. Transplant, Virginia Commonwealth University Hospitals, Richmond, VA, USA.
Abstracts

32-P
CENTERS WITH A VERY LOW PERCENTAGE OF BROADLY SENSITIZED CANDIDATES CAN HAVE A NEGATIVE IMPACT ON THE EFFICIENCY OF KIDNEY ALLOCATION.
1Research, United Network for Organ Sharing, Richmond, VA, USA; 2Cedars Sinai Comprehensive Transplant Center, HLA Laboratory, Los Angeles, CA, USA; 3Laboratory, UCSF Immunogenetics & Transplant Laboratory, San Francisco, CA, USA; 4Immunogenetics Center, UCLA, Los Angeles, CA, USA.

33-P
DETECTION OF ANTI-HLA ANTIBODY: COMPARATIVE EVALUATION OF LABScreen AND LIFECODES ANTIBODY LUMINEX ASSAYS.
Abdelhamid Liacini1,2,3, Luz Stamm1, Noureddine Berka1,2. 1Pathology & Laboratory Medicine, Tissue Typing Laboratory, Calgary Laboratory Services, Calgary, AB, Canada; 2Pathology & Laboratory Medicine, University of Calgary, Dammam, AB, Canada; 3Pathology & Laboratory Medicine, Histocompatibility & Immunogenetics Laboratory King (HIL) Fahad Specialist Hospital, Dammam, Saudi Arabia.

34-P
THE ACCEPTABLE REACTIVE CROSSMATCH (ARC), POST TRANSPLANT MONITORING AND ITS IMPACT ON KIDNEY TRANSPLANTATION.
Mayra Lopez-Cepero1, Victor Bowers2, Rajendra Baliga2, Charles Sanders2, Donna Becker1, Dawn Thompson1, Sandra Resto-Ruiz1, John Leone2. 1LifeLink Transplant Immunology Lab., LifeLink Foundation, Tampa, FL, USA; 2Tampa General Medical Group, Tampa General Hospital, Tampa, FL, USA.

35-P
PREDICTION OF HLA ANTIGEN MATCHING PROBABILITIES FOR PATIENTS BEING CONSIDERED FOR SOLID ORGAN TRANSPLANTS.
Martin Maiers1, John Freeman1, Alan Howard2, Dong-Feng Chen3. 1Bioinformatics Research, National Marrow Donor Program, Minneapolis, MN, USA; 2Immunobiology Research, Center for International Blood and Marrow Transplant Research, Minneapolis, MN, USA; 3Clinical Transplantation Immunology Laboratory, Department of Pathology, Duke University Medical Center, Durham, NC, USA.

36-P
WR18 MONOCLONAL ANTIBODY: A SINGLE ANTIBODY TO DETECT HLA DR, DP AND DQ ANTIGENS.
Deanna Manna, Anne Halpin, Patricia Campbell, Luis Hidalgo. Histocompatibility Laboratory, University of Alberta Hospital, Edmonton, AB, Canada.

37-P
FORMATION OF HLA ANTIBODIES IN NON-SENSITIZED PATIENTS AFTER IMMEDIATE GRAFT LOSS FOR NON-IMMUNOLOGICAL CAUSES.
Cindi G. Marchman, Sheree H. Waslaske, Carissa Hagy, Anthony M. Pinckney, Elise M. McPherson, Thomas G. Thompson, Omar Moussa. Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC, USA.
Abstracts

38-P
CORRELATION OF C1Q ASSAY AND LUMINEX SINGLE ANTIGEN TESTING WITH DSA.
Danielle Meehan, Angela Busacco, Myra Coppage. Lab Medicine-HLA Lab, University of Rochester Medical Center, Rochester, NY, USA.

39-P
INCREASING MFI CUTOFFS FOR UNACCEPTABLE ANTIGENS INCREASES ACCESS TO ACTUAL DECEASED DONOR CROSSMATCHES FOR THE SENSITIZED RECIPIENT.
Maureen Miller, Tod Alberghini, Michael Rewinski, Laurine Bow. Transplant Immunology Laboratory, Hartford Hospital, Hartford, CT, USA.

40-P
COST AND TIME SAVINGS FOR DECEASED DONOR HLA TYPING USING FROZEN PREPARED R-SSO TRAYS.
Michael Naglich, David Kramer, Robert Liwski, Alice VanOosterwijk, Neal DenHollander, Kathryn Tinckam. 1HLA Laboratory, University Health Network, Toronto, Canada; 2HLA Laboratory, QEII Health Sciences Center - Dalhousie University, Halifax, Canada.

41-P
CROSS MATCH OUTCOME AND ANTI-HLA SOLID STATE ANTIBODY ASSAYS: RESOLUTION OF DISCREPANT RESULTS IN DECEASED DONOR KIDNEY TRANSPLANTATION.
Allen J. Norin, David Hochman, Mary Mondragon-Escorpizo, Moro O. Salifu, Sharon Hess, Ballabh Das. 1Transplant Immunology & Immunogenetics Laboratory, SUNY Downstate Medical Center, Brooklyn, NY, USA; 2Medicine, SUNY Downstate Medical Center, Brooklyn, NY, USA.
Norin: Gen-Probe: Speakers Bureau.

42-P
RARE HLA ALLELES AND IMPACT ON HLA-MATCHING IN KIDNEY TRANSPLANTATION.
Giuseppina Ozzella, Elvira Poggi, Valentina Imbroglini, Luisa Mazzitelli, Martina Carducci, Domenico Adorno, Antonina Piazzza. 1Institute of Translational Pharmacology Unit of Rome S. Camillo Hospital, National Council of Researches, Rome, Italy; 2Regional Transplant Center of Lazio, for Vergata University of Rome, Rome, Italy.

43-P
RELATIONSHIP BETWEEN KIDNEY ALLOGRAFT REJECTION AND VARIOUS FACTORS INCLUDING PREOPERATIVE SOLUBLE HUMAN LEUKOCYTE ANTIGEN-G LEVELS.
Yongjung Park, Myoung soo Kim, Yu-Seun Kim, Haejin Kim, Hyon-Suk Kim. 1Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea; 2Research Institute for Transplantation, Yonsei University College of Medicine, Seoul, Republic of Korea.

44-P
ANTI-MICA DETECTION IN SOLID ORGAN RECIPIENTS, JUSTIFICATION FOR PRE TX-EVALUATION.
Timothy Williams, Cynthia Schall, Nell Field, Andrea Parkinson, Debra Schauss, Judy Knakiewicz, Judy Wysocki, Thomas Franks, Daniel Ramon. Department of Pathology, University of Michigan Health System, Ann Arbor, USA.
Abstracts

45-P
WHEN A DSA IS NOT A DSA: POSITIVE VIRTUAL CROSSMATCHES RESULTING IN ACTUAL NEGATIVE CROSSMATCHES.
Michael J. Rewinski, Julio Ortiz, Kalia Bared, Tod Alberghini, Laurine Bow. Transplant Immunology, Hartford Hospital, Hartford, CT, USA.

46-P
RENAL TRANSPLANTATION IN THE PRESENCE OF ANTI-HLA ANTIBODIES.
Dave Roelen1, Ajda Rowshani2, Simone Brand-Schaafl, Jacqueline vd Wetering2, Joke Roodnat2, Sophia Stein1, Willem Weimar2, Frans Claas1. 1Dept. Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands; 2Dept. of Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands.

47-P
A NEW SEQUENCING-BASED TYING METHOD FOR HIGH-THROUGHPUT HLA TYING AT INTERMEDIATE RESOLUTION.

48-P
THE IMPACT OF SERUM PRE-TREATMENTS AND C1Q ON LUMINEX SA RESULTS AND ITS CORRELATION WITH CELL BASED CROSSMATCH.
Sarah N. Schumacher1, D. Phelan1, T. Mohanakumar1,2. 1HLA Laboratory, Barnes-Jewish Hospital, St. Louis, MO, USA; 2Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.

49-P
A CUT-OFF FOR ANTIBODY STRENGTH TO PERFORM VIRTUAL CROSSMATCH AT KFHSD-DAMMAM: ASSESSMENT OF PREDICTIVE POTENTIAL OF A SOLID PHASE ASSAY IN PREDICTING CDC-AHG CROSSMATCHES.
Rodney Scott1, Ricardo Lopez1, Faisal Khan2, Noureddine Berka2, Dalal Abduladeem1, Ahmed Al Otaibi2, Kenana Al Ajlan1, Saber Al Zahrani1. 1HIL Pathology, King Fahad Specialist Hospital, Dammam, Eastern Province, Saudi Arabia; 2Departments of Pathology and Laboratory Medicine and Paediatrics, University of Calgary/Calgary Laboratory Services, Calgary, AB, Canada.

50-P
THE SURVEY: UTILIZING LOW RESOLUTION TYING TO PREDICT HIGH RESOLUTION TYING – A VIRTUAL TOOL.
Vijay K. Sharma1,2, Rex A. Friedlander1, Kejalben Ghiwala1, Cindy H. Park1, Sharon Austria1, Laura Baraian1, Brianne Olivieri1, Sue Tiongko1, Arvind K. Menon1, Darshana Dadhania1,2, Manikkam Suthanthiran1,2. 1Immunogenetics and Transplantation, The Rogosin Institute, New York, NY, USA; 2Department of Transplant Medicine, NYPH - Weill Cornell Medical College, New York, NY, USA.
Abstracts

51-P
NEGATIVE HLA DSA BY LUMINEX SOLID PHASE ASSAY AND POSITIVE DONOR CDC CROSSMATCH: A CROSSMATCH CONUNDRUM.
Vijay K. Sharma1,2, Rex A. Friedlander1, Blanca M. Ponce1, Arvind K. Menon1, Darshana Dadhania1,2, Manikkam Suthanthiran1,2. 1Immunogenetics and Transplantation Laboratory, The Rogosin Institute, New York, NY, USA; 2Department of Transplant Medicine, NYPH-Weill Cornell Medical College, New York, NY, USA.

52-P
CARDIAC TRANSPLANTATION OF HIGHLY SENSITIZED PATIENTS ACROSS C1Q NEGATIVE HLA ANTIBODIES.
Sheree H. Waslaske1, Lauren Nickels1, Cheryl L. Nasse1, E. Haywood Titchener1, Karen A. Cellars1, Andrew J. Savage IV2, Omar Moussa1. 1Pathology and Lab Medicine, Medical University of South Carolina, Charleston, SC, USA; 2Pediatric Cardiology, Medical University of South Carolina, Charleston, SC, USA.

53-P
SUCCESSFUL RENAL TRANSPLANTATION WITH POSITIVE CROSSMATCHES AND DONOR SPECIFIC HLA ANTIBODIES FOLLOWING HIGH DOSE IVIG THERAPY.
Qiuheng Zhang1, Raja Rajalingam1, Suzanne McGuire2, Elaine F. Reed1, Gerald Lipshutz2. 1UCLA Immunogenetics Center, Department of Pathology and Laboratory Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, USA; 2Surg-Liver & Pancreas Transplantation, UCLA David Geffen School of Medicine, Los Angeles, CA, USA.

54-P
FRACTIONATED DONOR CHIMERISM (FDC) ANALYSIS IN THE DETECTION AND TREATMENT OF GVHD IN SOLID ORGAN TRANSPLANTATION – DIAGNOSTIC AND THERAPEUTIC IMPLICATIONS.
Alexandra C. Amador, Jennifer McCue, Rogelio Gonzalez, Akin Tekin, Gennaro Selvaggi, Jennifer Garcia, Andreas G. Tzakis, Phillip Ruiz. Surgery-Transplant, University of Miami, Miami, FL, USA.

55-P
IMPACT OF DONOR SPECIFIC ANTIBODIES (DSA) IN RETRANSPLANTATION OF LIVER.
Todd Brennan1, Kadiyala Ravindra1, Dong-Feng Chen2, Deepak Vikraman-Sushama1, Abigail Martin1, Bradley Collins1, Debra Sudan1. 1Department of Surgery, Duke University Medical Center, Durham, NC, USA; 2Department of Pathology and Clinical Laboratories, Duke University Medical Center, Durham, NC, USA.

56-P
VIMENTIN AUTOANTIBODY DURING REJECTION IN AN HLA CHROMOSOME-IDENTICAL SIBLING RENAL TRANSPLANT RECIPIENT (RTR) – IDENTIFICATION OF LUMINEX HLA SINGLE ANTIGEN BEAD CROSSREACTIVITY.
James C. Cicciarelli, Nathan A. Lemp, Noriyuki Kasahara. Immunogenetics Laboratory, Mendez National Institute of Transplantation, Los Angeles, CA, USA.
Abstracts

57-P
HLA ANTIBODY AGAINST SELF AND DONOR HLA-C*04:01 MOLECULE: DSA OR NOT?
Zeying Du¹, Natasia Kowalkowski¹, Wuhua Wu¹, Kristin Dastych¹, Andres Jaramillo¹,², Sujata Gaitonde¹. ¹Pathology, University of Illinois at Chicago, Chicago, IL, USA; ²Histocompatibility Laboratory, Gift of Hope Organ & Tissue Donor Network, Itasca, IL, USA.

58-P
DSA IN THE ABSENCE OF POSITIVE FLOW CROSS-MATCH CAN PREDICT REJECTION PROCESS IN THE TRANSPLANTED KIDNEY: A CASE REPORT.
Salim Alqurashi¹, Khaled Alsaad², Abdullah Al-Sayyari¹, Dunia Jawdat², Ali Hajeerª, ¹Nephrology, King Abdulaziz Medical City, Riyadh, Saudi Arabia; ²Department of Pathology and Laboratory Medicine, King Abdulaziz Medical City, Riyadh, Saudi Arabia; ³Cord Blood Bank, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.

59-P
THE CLINICAL SIGNIFICANCE OF ANTI-HLA AND ANTI-MICA ANTIBODY DEVELOPMENT IN KIDNEY TRANSPLANTATION BY DYNAMIC MONITORING DURING FOUR YEARS FOLLOW-UP.
Jian Quan Jou. Urology Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.

60-P
PERSISTENT POST-TRANSPLANT DSA IDENTIFIES IMMUNOLOGICALLY HIGH RISK RECIPIENTS.
L. A. Bihari, J. G. Saltarrelli, J. Lappin, S. M. Katz, C. Van Buren, J. Eaton, N. Woolley, E. McKissick, R. H. Kerman. Department of Surgery, Baylor College of Medicine, Houston, TX, USA.

61-P
EVALUATION OF DONOR SPECIFIC C1q HLA ANTIBODY AS A MARKER FOR SEVERITY OF DISEASE AND RESPONSE TO TREATMENT OF ANTIBODY MEDIATED REJECTION IN FIVE CARDIAC TRANSPLANT RECIPIENTS.
Gautam Ramani¹, Vikram Bhasin², Debra Kukuruga², Allen Burke⁴. ¹Cardiology, University of Maryland Medical Center, Baltimore, MD, USA; ²Internal Medicine, University of Maryland Medical Center, Baltimore, MD, USA; ³Pathology, Immunogenetics Laboratory, University of Maryland Medical Center, Baltimore, MD, USA; ⁴Pathology, University of Maryland Medical Center, Baltimore, MD, USA.

62-P
HLA-DQ C1q BINDING DONOR SPECIFIC ANTIBODY (qDSA) ASSOCIATED WITH THE DEVELOPMENT OF CARDIAC ALLOGRAFT VASCULOPATHY (CAV).
Chih-Hung Lai¹, Nancy L. Reinsmoen¹, Robin Masukawa¹, Geraldine Ong¹, Qi Wang¹, Mehrnoush Naim¹, Matthew Rafiei², Lily Stern², Jon A. Kobashigawa². ¹HLA Lab, Cedars-Sinai Health System, Los Angeles, USA; ²Heart Transplant Program, Cedars-Sinai Health System, Los Angeles, CA, USA.
Abstracts

63-P
LOWER LEVEL OF ATP CONCENTRATION OF CD4+ T LYMPHOCYTES INDICATES A GREAT POSSIBILITY OF INFECTION FOR PATIENT AFTER RENAL TRANSPLANTATION BY USING CYLEX IMMUNOKNOW ASSAY.
Yang Li, Jun He. Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.

64-P
HEART TRANSPLANT OUTCOME IN RECIPIENT WHO DEVELOPED DONOR SPECIFIC ANTIBODIES (DSA) DE NOVO (CASE REPORT).
Andrew L. Lobashovsky1,2, Kevin M. Rosner1, Jacqueline A. O’Donnell3, Nancy G. Higgins1. 1Histocompatibility Laboratory, Indiana University Health, Methodist Hospital, Indianapolis, IN, USA; 2Medicine, Indiana University School of Medicine, Indianapolis, IN, USA; 3Cardiology, Methodist Hospital, Indianapolis, IN, USA.

65-P
MONITORING RENAL ALLOGRAFT RECIPIENTS BY LUMINEX C1q TESTING: ASSOCIATION WITH CLINICAL AND PATHOLOGICAL RESULTS.
John G. Lunz1, Ron Shapiro2, Parmjeet Randhawa1, Larry Jelinek1, Adriana Zeevi1. 1Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA; 2Surgery, University of Pittsburgh, Pittsburgh, PA, USA.

66-P
ALLOGRAFT INFLAMMATORY FACTOR-1 IN CARDIAC ISCHEMIA REPERFUSION INJURY.
Olga McDaniel1, Debbie A. Rigney1, Xinchun Zhou2, Larry S. McDaniel1, Giorgio Aru1, Curtis Tribble1, Walter H. Merrill1. 1Surgery, University of Mississippi Medical Center, Jackson, MS, USA; 2Pathology, University of Mississippi Medical Center, Jackson, MS, USA.

67-P
CUSTOMIZED HLA DONOR SPECIFIC ANTIBODY REPORT GENERATION.
Scott B. McDonald, Stan I. Mitchell. HLA Laboratory, Midwest Transplant Network, Westwood, KS, USA.

68-P
HEAT SENSITIVE “INTERFERING FACTOR” MASKS THE POST TRANSPLANT DETECTION OF DE NOVO DONOR SPECIFIC ANTIBODY.
Tracy T. McRacken1, Cynthia M. Spraggin1, Howard M. Gebel2, Robert A. Bray2. 1Transplantation, Sentara Norfolk General Hospital, Norfolk, VA, USA; 2Pathology, Emory University Hospital, Atlanta, GA, USA.

69-P
EFFICIENT C1q LUMINEX TESTING BY INITIALLY SCREENING FOR DONOR SPECIFIC ANTIBODY BY THE SINGLE ANTIGEN LUMINEX ASSAY.
Jennifer Mendiola, Lynsey Biondi, Michael Moritz, Robert Cirocco. HLA Lab, Lehigh Valley Health Network, Allentown, PA, USA.
Abstracts

**70-P**
IDENTIFICATION OF DQB1- AND DQA1-SPECIFIC ANTIBODIES WITH AN EXPANDED SET OF HLA CLASS II SINGLE ANTIGENS.
Justin W. Mostecki, Lioudmila Zaslavskaia, Ning Jiang, Ivan Balazs. R&D, Gen-Probe Transplant Diagnostics, Inc., Stamford, CT, USA.

**71-P**
BIOMARKERS, A NON-INVASIVE APPROACH FOR DIAGNOSIS OF REJECTION IN RENAL TRANSPLANT RECIPIENTS.
Afzal Nikaein1, Karen Roush2, Brandt Moore1, Richard Dickerman2,3, Jude Hunt1, Mark Lerman3.
1HLA Laboratory, Texas Medical Specialty, Inc., Dallas, TX, USA; 2HLA Laboratory, Methodist Hospital in Dallas, Dallas, TX, USA; 3Transplant, Medical City Dallas Hospital, Dallas, TX, USA.

**72-P**
C1q BINDING ASSAY: A SUPERIOR TOOL TO MONITORING ANTI-DQ DONOR SPECIFIC ANTIBODY REMOVAL THERAPY?
Kamal Abuqaurquob1, Timothy Williams1, Alan Leichtman2, Chisa Yamada1, Kevin M. Chan2, Milagros Samaniego-Picota2, Randall Sung3, Daniel Ramon1.
1Department of Pathology, University of Michigan Health System, Ann Arbor, USA; 2Department of Internal Medicine, University of Michigan Health System, Ann Arbor, USA; 3Department of Surgery, University of Michigan Health System, Ann Arbor, USA.

**73-P**
IMPROVING PERFORMANCE OF THE CYLEX IMMUKNOW ASSAY: APPLICATION OF LESSONS FROM PROFICIENCY TESTING (PT).

**74-P**
The C1q ASSAY IN RENAL POST-TRANSPLANT PATIENTS.
Meghan P. Riley, Justine L. Gaspari, Xuebin Yang, Ronald E. Domen, Carrie L. Mowery, Carolyn L. Fisher, Hiroko Shike. Pathology, Penn State Hershey Medical Center, Hershey, PA, USA.

**75-P**
DONOR SPECIFIC HLA-DQa ANTIBODY IN RENAL POST-TRANSPLANT PATIENTS.
Xuebin Yang, Justine L. Gaspari, Meghan P. Riley, Ronald E. Domen, Dennis F. Habig, Hiroko Shike. Pathology, Penn State Hershey Medical Center, Hershey, PA, USA.

**76-P**
SYNERGISTIC EFFECT OF COMPLEMENT FIXING AND NON-COMPLEMENT FIXING ANTIBODIES TO MAJOR HISTOCOMPATIBILITY CLASS I ANTIGENS IN DEVELOPMENT OF OBLITERATIVE AIRWAY DISEASE (CHRONIC LUNG ALLOGRAFT REJECTION).
Vijay Subramanian1, Masashi Takekaka1, Venkataswarup Tiriveedhi1, Andrew Gelman1, Alexander Patterson1, T. Mohanakumar2. 1Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA; 2Departments of Surgery and Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Abstracts

77-P
HIGHER RISK OF KIDNEY GRAFT FAILURE AFTER REJECTION IN THE PRESENCE OF ANTIBODIES AGAINST ANGIOTENSIN II TYPE 1 RECEPTOR (AT1R).
Michiko Taniguchi1, Lorita M. Rebellato2, Junchao Cai3, Paul G. Catrou2, Kimberly P. Briley2, Judy Hopfield1, Paul I. Terasaki3. 1Research II, One Lambda, Inc., Los Angeles, CA, USA; 2East Carolina University, Brody School of Medicine, Greenville, USA; 3Terasaki Foundation Laboratory, Los Angeles, CA, USA.

78-P
ANTI-HLA ANTIBODIES IN PEDIATRIC RECIPIENTS OF HEART ALLOGRAFTS.
George Vlad1, Eric Ho1, Charles Marboe1, Linda J. Addonizio2, Nicole Suciu-Foca1, Elena R. Vasilescu1. 1Pathology and Cell Biology, Columbia University, New York, NY, USA; 2Pediatrics, Columbia University, New York, NY, USA.

79-P
CORRELATION OF HLA ALLOEPITOPES WITH THE DEVELOPMENT OF DE NOVO DONOR SPECIFIC ANTIBODIES AFTER RENAL TRANSPLANTATION.
Chris Wiebe1,2, Tom Blydt-Hansen4, Ian Gibson3,5, Denise Pochinco3, David Rush1, Peter Nickerson1,2,3, 1Medicine, University of Manitoba, Winnipeg, Canada; 2Immunology, University of Manitoba, Winnipeg, Canada; 3Transplant Immunology Laboratory, Diagnostic Services of Manitoba, Winnipeg, Canada; 4Department of Pediatric and Child Health, University of Manitoba, Winnipeg, Canada; 5Pathology, University of Manitoba, Winnipeg, Canada.

80-P
THE ASSOCIATION BETWEEN DEVELOPMENT OF DE NOVO DONOR SPECIFIC HUMAN LEUKOCYTE ANTIGEN HLA ANTIBODIES (DSA) AFTER LUNG TRANSPLANTATION AND BRONCHIAL BIOPSY HISTOLOGICAL FINDINGS.
Medhat Askar1, Patrick Reville1, Lynne Klingman1, Aiwen Zhang1, Jesse Schold3, Marie Budev3, Kenneth McCurry4, Carol Farver5. 1Allogen Laboratories, Cleveland Clinic, Cleveland, USA; 2Quantitative Health Sciences, Cleveland Clinic, Cleveland, USA; 3Pulmonary, Allergy and Critical Care Medicine, Cleveland Clinic, Cleveland, USA; 4Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, USA; 5Anatomic Pathology, Cleveland Clinic, Cleveland, USA.

81-P
THE MAKING OF ANTI-HLA ANTIBODY REMOVAL MATRICES – A PERFORMANCE STUDY.
Michael C. Eades1, Rodney S. VanGundy1, Rebecca D. McAdams1, Curtis P. McMurtrey2, Steven J. Cate3, Steffen D. Sigler1, Aaron D. Rennels4, Kayla M. Lira1, William H. Hildebrand2, Rico Buchli1. 1R&D, Pure Protein LLC, Oklahoma City, OK, USA; 2Microbiology and Immunology, Oklahoma University Health Sciences Center, Oklahoma City, OK, USA.
82-P
BORTEZOMIB USE FOR ANTIBODY-MEDIATED REJECTION IN PEDIATRIC HEART TRANSPLANT.
Dong-Feng Chen1, Robert D.B. Jaquiss2, Andrew J. Lodge2, Michael P. Carboni3. 1Department of Pathology and Clinical Laboratories, Duke University Medical Center, Durham, NC, USA; 2Department of Surgery, Duke University Medical Center, Durham, NC, USA; 3Pediatric Cardiology, Duke Children’s Hospital, Durham, NC, USA.

83-P
GVHD IN MVT AND SMALL INTESTINAL TRANSPLANTATION HSCT AS SAVAGE THERAPY.
Deborah Cova, Alexandra Amador, Jennifer Garcia, Akin Tekin, David Levi, Genaro Selvaggi, Seigo Nishida, Andrea Tzakis, Phillip Ruiz. Surgery, University of Miami, Miami, FL, USA.

84-P
HLA MISMATCHES PROMOTE CLASS-SPECIFIC ANTI-DONOR ANTIBODY FORMATION IN RENAL TRANSPLANT PATIENTS.
Danielle Ladie, Kristina Krecko, Robert Scott, Mary Waybill, Harold Yang, Seth Narins. Transplant Surgery, PinnacleHealth, Harrisburg, PA, USA.

Yang: Novartis: Grant Research; Speakers Bureau; Astellas: Grant Research.

85-P
HLA HAPLOTYPE FREQUENCIES IN SAUDI ARABIA FOR DESIGN OF A SAUDI STEM-CELL REGISTRY.
Moheeb Al-Awwami1, Mahmoud Aljurf2, Hind Al-Humidan3, Hassan El-Solh4, Khalid Almeshari5,1, Amal Al-Seraiphy6, Mouhab Ayas4, Ghuzayel Aldawarsi7, Fouad Al-Dayel8, John Freeman8, Abeer Madbouly8, Martin Maiers8, Loren Gragert8. 1Histocompatibility and Immunogenetics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; 2Adult HSCT Program, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; 3Stem Cell Cord Blood Bank Laboratory, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; 4Pediatric BMT Program, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; 5Kidney and Pancreas Transplant Department, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; 6Bioinformatics Research, National Marrow Donor Program, MN, USA.

86-P
HLA-B*15:151 IS A B70 ANTIGEN THAT CROSS REACTS WITH B41 AND B42 ANTIGENS.
Mohammad Awaji1, Adel Shawhatti1, Ridney Scott1, Faisal Khan2,3,4, Noureddine Berka2,3. 1Histocompatibility and Immunogenetics Laboratory, King Fahad Specialist Hospital, Dammam, Saudi Arabia; 2Tissue Typing Laboratory, Calgary Laboratory Services, Calgary, AB, Canada; 3Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada; 4Department of Paediatrics, University of Calgary, Calgary, AB, Canada.
Abstracts

87-P
IDENTIFICATION OF NEW HLA ALLELES BY SEQUENCE BASED TYPING: B*40:206, C*02:58, DQB1*03:40, DQB1*06:50.
Kai Cao, Edward Guerrero, Weicheng Zhao, Dana Willis, Titus Barnes, Nathan Smith, Siqi Liao, Daly Moul, David Partlow, Pedro Cano, Marcelo Fernández-Viña. Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

88-P
eNOS PPOLYMORPHISM UN ASTHMATIC PATIENTS.
Margarida M.T.C. Cortez e Castro1, Joana Ferreira2, José Albuquerque2, Manuel Bicho2. 1ImmunoAllergy, CHLN-HSM, Lisbon, Portugal; 2Genetic Department, Lisbon Medical School, Lisbon, Portugal.

89-P
HLA-E VARIATION SITES AND TRANSITIONAL CELL CARCINOMA OF THE BLADDER IN BRAZILIANS.
Luciana C. Veiga-Castelli1, Athamy Sarah P. Cruz2, Moisés M. Inacio2, Erick C. Castelli2, Eduardo A. Donadi1. 1Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil; 2Instituto de Ciencias Biologia, Departamento de Biologia Geral, Universidade Federal de Goiás, Goiânia, Goiás, Brazil.

90-P
MICA AND MICB: ANALYSIS OF DISEASE-ASSOCIATED ALLELES AND GENE EXPRESSION LEVELS.

91-P
THE KIR BB HAPLOTYPE IS ASSOCIATED WITH SUSCEPTIBILITY TO CLASSIC PARS PLANITIS (CPP) IN MEXICAN MESTIZO PATIENTS.
Hilario Flores-A1, Carmen Aláez1, Luz Elena Concha2, Lourdes Arellanes2, David Senitzer4, Clara Gorodezky1. 1Dept. of Immunology & Immunogenetics, InDRE, Secretary of Health, Mexico City, DF, Mexico; 2Inflammatory Eye Disease Clinic, Asociación para Evitar la Ceguera en México, I A.P. “Dr. Luis Sánchez Bulnes”, Mexico City, DF, Mexico; 3HLA Laboratory, City of Hope National Medical Center, Duarte, CA, USA.

92-P
KIR2DS2 GENE CONIFRS SUSCEPTIBILITY TO LEPROMATOUS LEPROSY (LL) IN MEXICAN PATIENTS.
Carmen Aláez1, Hilario Flores-A1, Andrea Munguía1, Araceli Rodríguez1, David García1, Myrna Rodríguez2, Fermín Jurado2, Obdulia Rodríguez2, David Senitzer3, Clara Gorodezky1. 1Dept. of Immunology & Immunogenetics, InDRE, Secretary of Health, Mexico City, Mexico; 2Dermatology, Centro Dermatológico “Dr. Ladislao de la Pascua”, Mexico City, Mexico; 3HLA Laboratory, City of Hope National Medical Center, Duarte, CA, USA.
Abstracts

93-P
HLA HAPLOTYPE FREQUENCIES AND MATCH RATES FOR THE CANADIAN ONEMATCH REGISTRY.
Loren Gragert¹, Martin Maiers¹, Sue Smith², Yves Garcia³, Alan DeKoven⁴, Meagan Green⁴, Donna Killeen², Beth Amer², Jennifer Philippe⁴, Sofia Tavoularis³,⁴. ¹Bioinformatics Research, National Marrow Donor Program, Minneapolis, MN, USA; ²OneMatch Stem Cell and Marrow Network, Canadian Blood Services, Ottawa, Canada; ³Canadian Blood Services, Head Office, Ottawa, Canada; ⁴University of Ottawa, Faculty of Medicine, Ottawa, Canada.

94-P
THE IMPACT OF HLA HIGH RESOLUTION TYPING MISMATCHING OF DONOR-RECIPIENT PAIRS ON OUTCOME OF UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION.
Jun He. Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.

95-P
KIR GENE-CONTENT VARIATION IN 113 WORLDWIDE POPULATIONS.
Jill A. Hollenbach¹, Derek Middleton². ¹Center for Genetics, Children’s Hospital Oakland Research Institute, Oakland, CA, USA; ²Transplant Immunology, Royal Liverpool University Hospital, Liverpool, United Kingdom.

96-P
COMMON AND WELL-DOCUMENTED (CWD) ALLELES OF HUMAN LEUKOCYTE ANTIGENS-A, B, C, DRB1, DQB1 LOCI FOR CHINESE HAN POPULATION DO NOT QUITE CORRELATE WITH THE ASHI CWD ALLELES.
Yang Li, Jun He, Xiaoqing Bao, Qiaocheng Qiu, Xiaoni Yuan, Chao Xu. Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.

97-P
INTERLEUKIN 17 GENE POLYMORPHISM AND CHRONIC KIDNEY ALLOGRAFT FAILURE.
Abdelhamid Liajini¹,²,³, Duai Ibrahim⁴, Faridi Rehan⁴, Faisal Khan¹,²,⁵, Aylin Sar²,⁴, Serdar Yilmaz²,⁴, Nourreddine Berka¹,². ¹Pathology and Laboratory Medicine, Tissue Typing Laboratory, Calgary Laboratory Services, Calgary, AB, Canada; ²Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada; ³Pathology and Laboratory Medicine, Histocompatibility & Immunogenetics Laboratory King Fahad Specialist Hospital, Dammam, Saudi Arabia; ⁴Medicine, University of Calgary, Calgary, AB, Canada; ⁵Pathology and Laboratory Medicine, Paediatrics, University of Calgary, Calgary, AB, Canada; ⁶Pathology and Laboratory Medicine, Division of Transplantation, University of Calgary, Calgary, AB, Canada.

98-P
TNF-α PROMOTER ALLELES WITHIN CONSERVED HLA-HAPLOTYPES.
Daniel Fürst, Christine Zollkofe, Hubert Schrezenmeier, Joannis Mytilineos. Transplantation Immunology, IKT Ulm, Ulm, Germany.
Abstracts

99-P  
INCIDENCE OF THE CLINICALLY SIGNIFICANT NULL ALLELE DRB5*01:08N IN THE CANADIAN POPULATION OF SOUTHERN ALBERTA.  
Charlene Ott, Luz Stamm, Kim Larlee, Noureddine Berka. Tissue Typing, Calgary Laboratory Services, Calgary, AB, Canada.

100-P  
KILLER CELL IMMUNOGLOBULIN LIKE RECEPTORS DISTRIBUTION IN HEALTHY BRAZILIAN CAUCASIAN KIDNEY DONORS.  
Marcio M. Moraes, Alessandro Pirri, Maria da Graça Bicalho. Genetics, Federal University of Paraná, Curitiba, Paraná, Brazil; Genetics, Federal University of Paraná, Curitiba, Paraná, Brazil; Genetics, Federal University of Paraná, Curitiba, Paraná, Brazil.

101-P  
IDENTIFICATION OF NOVEL ASSOCIATIONS BETWEEN DRB1*01 AND DRBs USING MOLECULAR METHODS.  
Stephanie Souza¹, Pamela Palmer¹, Melissa Marlowe¹, Robin Medis¹, Scott Carter², Edward P. Scott², Robert O. Endres¹. ¹HLA Laboratory, Blood Systems Laboratories, Tempe, AZ, USA; ²Key Biologics, LLC, Memphis, TN, USA.

102-P  
KIR REPERTOIRE OF THE HELLENIC CORD BLOOD BANK (HCBB) INVENTORY.  
Maria Spyropoulou-Vlachou¹, Amalia Dinou², Theofanis Chatzistamatiou³, Efstathios Michalopoulos³, Andreas Papassavas³, Catherine Stavrakopoulos-Giokas³. ¹Immunology Dpt-Tissue Typing Lab, “Alexandra” General Hospital of Athens, Athens, Greece; ²Hellenic Cord Blood Bank, Biomedical Research Foundation Academy of Athens, Athens, Greece.

103-P  
GENETIC DIVERSITY WITHIN THE U.S. POPULATION: 67% OF HAPLOTYPES IDENTIFIED BY SEGREGATION ARE SINGLETONS.  
Bin Tu¹, Nicole Leahy², Ruyan Yang¹, Nuri Cha¹, Kanthi Kariyawasam¹, Ellen Tvrdy³, Dondi Pulse-Earle³, Martin Maiers², Jennifer Ng¹, Joanne Kurtzberg¹. ¹CW Bill Young Marrow Donor Recruitment and Research Program, Georgetown University, Rockville, MD, USA; ²National Marrow Donor Program, Minneapolis, MN, USA; ³Duke University, Chapel Hill, NC, USA.

104-P  
NON-CODING REGIONS OF HLA-B AND -C CONTAIN HAPLOTYPE SPECIFIC POLYMORPHISMS: SHOULD UNRELATED STEM CELL TRANSPLANTS INCLUDE MATCHING OF NON-CODING REGIONS?  
Carla M. Wirtz¹, Hayley M. Hogan¹, Mehdi Alizadeh², David Senitzer², Ketevan Gendzekhadze³, Brian S. Iglehart¹, Curt T. Lind³, Dmitrios Monos³, Ian Humphreys⁶, David C. Sayer¹. ¹Conexio Genomics, Fremantle, Western Australia, Australia; ²Immunogenetics and Histocompatibility, EFS Rennes, Rennes, France; ³Histocompatibility Laboratory, City of Hope National Medical Centre, Duarte, USA; ⁴Immunogenetics Laboratory, Johns Hopkins University School of Medicine, Baltimore, USA; ⁵Immunogenetics, Childrens Hospital of Philadelphia, Philadelphia, USA; ⁶Tissue Typing, South Australian Red Cross, Adelaide, Australia.
Abstracts

105-P
ESTABLISHMENT OF GENOTYPING METHOD FOR HUMAN NEUTROPHIL ANTIGEN OF HNA-1 SYSTEM BY PCR-SBT.
Xin Ye, Haoqian Ding. Guangzhou Blood Center, Guangzhou Blood Center, Guangzhou, China.

106-P
MICA-129 GENOTYPE DISTRIBUTION AND THE INFLUENCE OF RACE AND DISEASE STATE ON DISTRIBUTION.
Aiwen Zhang¹, Megan Dunlap², Amy Nowacki³, Dawn Thomas¹, Paul Kawczak¹, John McMichael¹, Roanld Sobecks¹, Medhat Askar¹. ¹Allogenous Laboratories, Cleveland Clinic, Cleveland, USA; ²Biology, The Ohio State University, Columbus, United Arab Emirates; ³Quantitative Health Sciences, Cleveland Clinic, Cleveland, USA; ⁴Hematologic Oncology and Blood Disorders, Cleveland Clinic, Cleveland, USA.

107-P
NOT ONLY SUITABLE HLA MATCHING, BUT VERY COST EFFECTIVE CORD BLOOD BANK.
Hind Al-Humidan¹, Morad Al-Kaff¹, Fadi Alzayer², Moheeb Al-Awwami². ¹Stem Cell Cord Blood Laboratory, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; ²Histocompatibility and Immunogenetics Laboratory, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

108-P
BONE MARROW NUCLEATED ERYTHROCYTES SELECTION AND ENGRAFTMENT EVALUATION.
Yenhui Chang, Cherry Jo Pascual, Perla Alonzo, Wilfredo Chamizo. Pathology and Laboratory Medicine, All Childrens Hospital, St. Petersburg, FL, USA.

109-P
DECLINE OF HLA ANTIBODIES IN A HEMATOPOIETIC STEM CELL TRANSPLANT PATIENT.
Robert O. Endres¹, Arthur D. Hoffman¹, Ian Scott¹, Stephanie Souza¹, Melissa Marlowe¹, Robin Medis¹, Veena D. Fauble², James L. Slack². ¹HLA Laboratory, Blood Systems Laboratories, Tempe, AZ, USA; ²Blood and Marrow Transplant Program, Mayo Clinic Hospital, Phoenix, AZ, USA.

110-P
CHIMERISM KINETIC STUDIES OF BMCD3+ BY REAL TIME PCR (QPCR) MAY PREDICT THE OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION.
Soudabeh Etessami¹, Laima Gaidulis¹, Joycelynne M. Palmer², Yan Shen², David Senitzer¹. ¹Histocompatibility, City of Hope, Duarte, CA, USA; ²Division of Biosatistic, City of Hope, Duarte, CA, USA.

111-P
IMPACT OF SOME NEONATAL FACTORS ON THE QUALITY OF CORD BLOOD UNITS (CBU) IN THE MEXICAN ALTRUISTIC CORD BLOOD BANK-BACECU.
Fernanda Pérez, Alejandra Vázquez, Danaéé Rodríguez, Eduardo Sánchez, Elizabeth Solis, Hilario Flores, Jesús Rivera, Clara Gorodezky. Dept. of Immunology & Immunogenetics, InDRE, Secretary of Health, Mexico City, Mexico.
Abstracts

112-P  
HLA-DR53 NULL (DRB4*03:01N) ALLELE IN TWO UNRELATED INDIVIDUALS.  
Elly Johnson1, Donna Rich-Sperling1, Twyla Pearce1, Jianping Li2, Qingyong Xu1. 1Lab Medicine, St. Paul's Hospital, Saskatoon, Canada; 2Pathology & Lab Medicine, The Ottawa Hospital, Ottawa, Canada.

113-P  
SEARCHING UNRELATED DONORS FOR HPC TRANSPLANTATION. EXPERIENCE IN A PUBLIC PEDIATRIC TRANSPLANT CENTER IN BUENOS AIRES, ARGENTINA.  
Cintia Yanina Marcos1, Cecilia Gamba1, Daniela Patricia Fernandez Souto1, Raquel Noemí Staciuk2, Silvina Laura Kuperman1. 1Hemoterapia, Hospital de Pediatría S.A.M.I.C. “Prof. Dr. J. P. Garrahan”, Buenos Aires, Argentina; 2Unidad de Trasplante de Médula Osea, Hospital de Pediatría S.A.M.I.C. “Prof. Dr. J. P. Garrahan”, Buenos Aires, Argentina.

114-P  
THE EFFECT OF AGE, GENDER AND TYPING RESOLUTION ON THE PROBABILITY OF STEM CELL DONATION.  
Carlheinz R. Mueller1, Ulrike Feldmann1, Werner Bochtler1, Susanne Morsch2, Alexander Schmidt3. 1Zentrales Knochenmarkspender-Register Deutschland, ZKRD, Ulm, Germany; 2Stiftung Knochenmark- und Blutstammzellspende Deutschland, SKD, Birkenfeld, Germany; 3Deutsche Knochenmarkspenderdatei, DKMS, Tübingen, Germany.

115-P  
VALIDATION OF THE 5-LOCUS MATCHING PREDICTIONS OF OptiMatch® BASED ON OVER 38,500 HIGH-RESOLUTION TYPING RESULTS.  
Werner Bochtler, Hans-Peter Eberhard, Ulrike Feldmann1, Hans-Georg Rist2, Carlheinz R. Mueller1. 1Zentrales Knochenmarkspender-Register Deutschland, ZKRD, Ulm, Germany.

116-P  
A DRB1*03/DRB1*08 ALLELE RECOMBINATION WITHIN EXON 2.  
Lucie Richard. Stem Cell and Reference Laboratory, Hema-Quebec, Saint-Laurent, QC, Canada.

117-P  
NGSengine: THE ULTIMATE TOOL FOR NGS HLA-TYPING.  
Rozemuller: GenDx: Employee; Stockholder. Penning: GenDx: Employee. Mulder: GenDx: Employee; Stockholder.

118-P  
ANTI-HLA ANTIBODY IN A GROUP OF UNRELATED HSCT DONOR/RECIPIENT PAIRS MISMATCHED IN THE HLA ALLELE.  
Urszula Siekiera1, Alicja Dobrowolska1, Miroslaw Markiewicz2, Anna Koclenga2, Monika Dzierzak-Mieta2, Slawomira Kyrucz-Krzemien2. 1HLA&Immunogenetic Lab, Regional Blood Center and Blood Treatment, Katowice, Poland; 2Dpt. of Hematology and BMT, Medical University of Silesia, Katowice, Poland.  
Siekiera: Blood Center: Other; HLA Lab Director. Dobrowolska: Blood Center: Employee. Markiewicz: Medical University of Silesia: Other: Clinician.
Abstracts

119-P
COMPARISON OF METHODOLOGIES TO REDUCE RITUXIMAB INTERFERENCE DURING FLOW CYTOMETRIC CROSSMATCH TESTING.
Stephanie Souza¹, Patrick Ching¹, Robert O. Endres¹, Leon L. Su², Riccardo Valdez³. ¹HLA Laboratory, Blood Systems Laboratories, Tempe, AZ, USA; ²Blood Systems, Inc., Scottsdale, AZ, USA; ³Mayo Clinic in Arizona, Phoenix, AZ, USA.

120-P
A “NEW” APPROACH TO RELATED BONE MARROW DONORS.
Lynda Thompson, Linda McEneny. Histocompatibility Lab, McMaster University Medical Centre, Hamilton, ON, Canada.

121-P
PROSPECTIVE HEMATOPOIETIC STEM CELL RECIPIENT TYPING REVEALED AN INHERITED NOVEL DQB1 ALLELE – RAISING QUESTIONS FOR NMDP POTENTIAL DONOR SEARCHING.
Runying Tian, Angelica DeOliveira, Gansuvd Balgansuren, Dong-Feng Chen. Department of Pathology and Clinical Laboratories, Duke University Medical Center, Durham, NC, USA.

122-P
CONSIDERING HLA-C MATCHING FOR SINGLE CORD BLOOD UNIT (CBU) TRANSPLANTS.
Kevin V. Tram, Jane Kempenich, Jason Dehn. Scientific Services, National Marrow Donor Program, Minneapolis, MN, USA.

123-P
HLA DIVERSITY IN A CHILEAN POPULATION.
Paula Y. Arnold¹, Christy C. Embrey¹, Fernandez-Vina Marcelo², Victoria Turner¹. ¹HLA Laboratory, Pathology, St. Jude Children’s Research Hospital, Memphis, TN, USA; ²Department of Pathology, Blood Bank, Stanford University, Palo Alto, CA, USA.

124-P
HIGH RESOLUTION TYPING WITH COMBINED METHODS OF SSO AND SSP.
Qingyong Xu¹,², Donna Rich-Sperling², Elly Johnson², Terry Akister³, Jianping Li³. ¹Pathology & Lab Medicine, University of Saskatchewan, Saskatoon, Canada; ²Lab Medicine, St. Paul’s Hospital, Saskatoon, Canada; ³Pathology & Lab Medicine, The Ottawa Hospital, Ottawa, Canada.

125-P
QUANTITATIVE PCR CHIMERISM METHOD DETECTING MULTIPLE HSCT DONORS.
Ketevan Gendzekhadze, Arisa Oki, David Senitzer. HLA, City of Hope, Duarte, CA, USA.

126-P
CHIMERISM ANALYSIS BY DROPLET DIGITAL PCR.
Lawrence Jennings¹,², David George¹, Min Yu¹, Frederick Smith¹,². ¹Pathology, Children’s Memorial Hospital, Chicago, IL, USA; ²Pathology, Northwestern University, Chicago, IL, USA.
Abstracts

127-P
A MULTIPLEX QUANTITATIVE PCR ASSAY FOR RAPID IDENTIFICATION OF INFORMATIVE MARKERS FROM MULTIPLE DONORS FOR STEM CELL TRANSPLANT ENGRAFTMENT MONITORING.
Christopher L. Sigua, Persis P. Wadia, Douglas A. Bost. Development, Celera, Alameda, CA, USA.

128-P
INHIBITION OF TCR SIGNALING BY RECOMBINANT ILT3Fc PROTEIN.
George Vlad, Chi-Chao Chang, Zhuoru Liu, Muyang Li, Nicole Suciu-Foca. Pathology and Cell Biology, Columbia University, New York, NY, USA.

129-P
A NEW, RAPID METHOD OF HLA-DP TYPING AND VIRTUAL CROSSMATCH.
Zachary Antovich, Roland Russnak, Elizabeth King, Ngoc Ly, Kai Quinto, Danny Youngs, Mohamed Elrefai, Paul Warner, F. Carl Grumet. 1Diagnostics, Linkage Biosciences, Inc., South San Francisco, CA, USA; 2Histocompatibility Laboratory, Puget Sound Blood Center, Seattle, WA, USA; 3Pathology, Stanford University, Stanford, CA, USA.

130-P
RESIDUE 81 CONFERS A RESTRICTED C-TERMINAL PEPTIDE BINDING MOTIF IN HLA-B*44:09.
Trevor Huyton, Heike Schumacher, Rainer Blasczyk, Christina Bade-Doeding. Institute for Transfusion Medicine, Hannover Medical School, Hannover, Germany.

131-P
PRELIMINARY IN-VITRO DATA SUPPORTING THE CONCEPT OF PEPTIDE EXCHANGE BY CELL SURFACE HLA-A*02:01.
Richard Battle, Malcolm Clench, Nicola Woodroffe, Clark Brendan. 1Biomedical Research Centre, Sheffield Hallam University, Sheffield, United Kingdom; 2Transplant Immunology, St James’ University Hospital, Leeds, United Kingdom.

132-P
COMPARISON OF DNA QUALITY, CONCENTRATION AND PROCESSING TIMES USING MAXWELL® 16 AND MAXWELL® CSC AUTOMATED NUCLEIC ACID EXTRACTION SYSTEMS.
Cristopher Cowan, Jeffrey Franz, Christine Newton, Gregg Cameron, Erin McCombs. Integrated Solutions and Engineering, Promega Corporation, Fitchburg, WI, USA.
Abstracts

133-P PERFORMANCE EVALUATION OF LIFECODES-RBC ASSAY FOR GENOTYPING OF TRANSPLANT PATIENTS.
Catherine Gebhart¹, Sally Schumacher¹, Sophie Hauxwell¹. ¹Molecular Diagnostics, The Nebraska Medical Center, Omaha, NE, USA; ²Pathology and Microbiology, The University of Nebraska Medical Center, Omaha, NE, USA.

134-P HEIGHTENED EXPRESSION OF NOD1 GENE IN PRE-IMPLANTATION BIOPSIES IS ASSOCIATED WITH DELAYED GRAFT FUNCTION.
Amador Goncalves-Primo¹, Vinicius Andrade-Oliveira¹,², Érika F. Campos¹,², José O. Medina-Pestana³, Hélio Tedesco-Silva³, Maria Gerbase-DeLima¹,². ¹Immunogenetics Institute, AFIP, São Paulo, SP, Brazil; ²Immunology, Microbiology, Parasitology, Universidade Federal de São Paulo, São Paulo, SP, Brazil; ³Hospital do Rim e Hipertensão, Fundação Oswaldo Ramos, São Paulo, SP, Brazil.

135-P ASSOCIATION OF CYP46 AND HLA DRB1*03 GENES IN ANOREXIC PATIENTS.
Alberto J. Leon¹, Victoriano J. Leon², Manuel Delgado³, Ana Alejandra Cordero³. ¹Division of Experimental Therapeutics, Toronto General Research Institute, Toronto, ON, Canada; ²Servicio de Análisis Clínicos, Hospital Universitario de Salamanca, Salamanca, Spain; ³UTCA Servicio Endocrino y Nutricion, Hospital Universitario de Salamanca, Salamanca, Spain.

136-P POLYMORPHISM SER326CYS OF GEN hOGG1 IN BLADDER CANCER PATIENTS.
Alberto J. Leon¹, Victoriano J. Leon², Javier Garcia³, Manuel Urrutia³. ¹Division of Experimental Therapeutics, Toronto General Research Institute, Toronto, ON, Canada; ²Servicio de Análisis Clínicos, Hospital Universitario de Salamanca, Salamanca, Spain; ³Servicio de Urología, Hospital Universitario de Salamanca, Salamanca, Spain.

137-P SINGLE MOLECULE REAL-TIME SEQUENCING OF FULL LENGTH HLA CLASS I GENES – THE PROMISE AND CURRENT REALITY.
Curt Lind¹, Kate Mackiewicz¹, Jamie Duke¹, Ariella Sasson¹,², Swati Ranade³, Anand Sethuraman⁴, Jason Chin⁴, Jeff Robinson⁴, Dimitri Monos¹,². ¹Department of Pathology and Laboratory Medicine, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA; ²Bioinformatics Core, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA; ³Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA; ⁴Pacific Biosciences, Menlo Park, CA, USA.

138-P ADAPTATION OF THE MAXWELL® 16 BLOOD LEV DNA PURIFICATION KIT WITH THE MAXWELL® CSC FOR USE IN BUCCAL SWAB DNA ISOLATION FOR HISTOCOMPATIBILITY TESTING.
Tracy Fisher, Stephanie Wallace, Rita Glumm, Jennifer J. Schiller. Histocompatibility and Immunogenetics, BloodCenter of Wisconsin, Milwaukee, WI, USA.
Abstracts

139-P  ANALYSIS OF THE SEROLOGICAL REACTIVITY AND HAPLOTYPES OF HLA-B*37:02 ALLELE.
Ahmed Salman¹, Dawn Thomas², Alan Smerglia², Gary Teresi², John McMichael², Medhat Askar².
¹Faculty of Medicine, Cairo University, Cairo, Egypt; ²Allogen Laboratories, Cleveland Clinic, Cleveland, USA.

140-P  DELETION OF UNCONFIRMED RARE ALLELES, C*03:12 AND C*15:20.
Elizabeth Beduhn¹, Ana Lazaro³, Tatiana Lebedeva³, Michelle Setterholm¹, Jane Kempenich¹.
¹Scientific Services, National Marrow Donor Program, Minneapolis, MN, USA; ²Department of Pediatrics, C.W. Bill Young Marrow Donor Research and Recruitment Program, Georgetown University Medical Center, Washington, DC, USA; ³HLA Laboratory, American Red Cross, Northeast Division, Dedham, MA, USA.

141-P  ASSOCIATION BETWEEN HLA AND THE PRODUCTION OF ANTI-HLA ANTIBODIES.
Érica A. Pereira, Patricia K. Saito, Roger H. Yamakawa, Sueli D. Borelli. Basic Science of Healthy, State University of Maringa, Maringa, Brazil.

142-P  DUFFY BLOOD-GROUP SYSTEM: ASSOCIATION OF Fyα ANTIGEN WITH CHRONIC KIDNEY DISEASE.
Roger H. Yamakawa¹, Patrícia K. Saito¹, Cinara C.B. Mattos², Fabiana Nakashima², Ana I.C. Ferreira², Luiz C. Mattos², Sueli D. Borelli¹. ¹Basic Science of Healthy, State University of Maringa, Maringa, Brazil; ²Department of Molecular Biology, Faculty of Medicine of São José do Rio Preto, São José do Rio Preto, Brazil.

143-P  ACCURACY OF HLA TYPING ON CORD BLOOD UNITS: SAMPLE SWITCHES ARE AN INCREASING EVENT.
Jing Cao¹, Craig Malmberg¹, Lesa Foley¹, Carly K. Carozza², Susan Hsu², Michelle Setterholm¹.
¹Scientific Services, National Marrow Donor Program, Minneapolis, MN, USA; ²Histocompatibility/Molecular Genetics, American Red Cross, Penn-Jersey Blood Services Region, Philadelphia, PA, USA.

144-P  RE-READING A COMPARATIVE STUDY RESULTS OF HLA-DQB1* ALLELES GENOTYPING.
Paulo R. Costantino, Sibelle B. Mattar, Maria da Graça Bicalho. Genetics, Federal University of Paraná, Curitiba, Paraná, Brazil.

145-P  NOTCH4 POLYMORPHISMS, FUNCTIONAL ASSESSMENT AND ASSOCIATIONS WITH BREAST CANCER SUSCEPTIBILITY.
Abstracts

146-P
ASSOCIATION OF HLA-LINKED LYMPHOMA RISK MARKERS WITH CHILDHOOD LYMPHOBLASTIC LEUKEMIA.
Amy E. Kennedy¹, Sandeep K. Singh¹, Michael E. Scheurer², M. Fatih Okcu², M. Tevfik Dorak¹.
¹Department of Environmental and Occupational Health, Florida International University, Robert Stempel College of Public Health and Social Work, Miami, FL, USA; ²Department of Pediatrics, Texas Children’s Cancer Center, Baylor College of Medicine, Houston, TX, USA.

147-P
EXAMINATION OF HLA-B, -DRA AND -DQA1 EXPRESSION LEVELS IN B-LYMPHOBLASTOID CELL LINES (B-LCL) HOMOZYGOS FOR CONSERVED EXTENDED HAPLOTYPES (CEH).

148-P
HLA REGION AND BREAST CANCER SUSCEPTIBILITY: RE-ANALYSIS OF CANCER GENETIC MARKERS OF SUSCEPTIBILITY (CGEMS) STUDY RESULTS.

149-P
TIME AIN’T ON OUR SIDE: REAL-TIME PCR FOR DECEASED DONOR TYPINGS.
Elaine F. O’Shields, David F. Kiger, Michael D. Gautreaux. HLA/Immunogenetics Laboratory, Wake Forest School of Medicine, Winston-Salem, NC, USA.

150-P
A SYSTEMATIC ANALYSIS OF THE LAST DECADE OF THE HLA DISEASE ASSOCIATION LITERATURE.
Jill Hollenbach. Center for Genetics, Children’s Hospital Oakland Research Institute, Oakland, CA, USA.

151-P
SALIVA COLLECTED USING THE ORAGENE® FAMILY OF PRODUCTS AS A RELIABLE SOURCE OF DNA FOR HLA TYPING USING NEXT GENERATION SEQUENCING.

152-P
HLA FREQUENCY IN CORD BLOOD UNITS COLLECTED AT KAIMRC HAVE SIMILAR HLA FREQUENCY TO THE SAUDI POPULATION AT LARGE.
Dunia Jawdat¹,², Hanan Al-Anazi³, Abdullah Shubaili³, Paul Sutton³, Aisha Al-Anazi³, Ali Hajeer³,⁴. ¹Cord Blood Bank, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia; ²College of Medicine, King Saud Bin Abdulaziz University, Riyadh, Saudi Arabia; ³Pathology/Immunology, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Abstracts

153-P
DIFFICULT TO MATCH DECEASED DONORS WITH THE SAUDI RECIPIENTS: DIFFERENT HLA TYPES.
1Cord Blood Bank, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia; 2College of Medicine, King Saud Bin Abdulaziz University, Riyadh, Saudi Arabia; 3Pathology and Laboratory Medicine, King Abdulaziz Medical City, Riyadh, Saudi Arabia.

154-P
AB ONLY DONORS – AN UNTAPPED RESOURCE.
Jane H. Kempenich, Katie Howe, Tami Maus, Kevin V. Tram, Kimberly Wadsworth, Jason Dehn. Scientific Services, National Marrow Donor Program, Minneapolis, MN, USA.

155-P
HLA DQB1* IN ANOREXIC PATIENTS OF CASTILLA Y LEON (SPAIN).
Alberto J. Leon1, Victoriano J. Leon2, Manuel Delgado3, Ana Alejandra Cordero3. 1Division of Experimental Therapeutics, Toronto General Research Institute, Toronto, ON, Canada; 2Servicio de Analisis Clinicos, Hospital Universitario de Salamanca, Salamanca, Spain; 3UTCA Servicio Endocrino y Nutricion, Hospital Universitario de Salamanca, Salamanca, Spain.

156-P
DPB1* ALELES IN ANOREXIC PATIENTS AND CONTROL IN CASTILLA YLEON (SPAIN).
Alberto J. Leon1, Victoriano J. Leon2, Manuel Delgado3, Ana Alejandra Cordero3. 1Division of Experimental Therapeutics, Toronto General Research Institute, Toronto, ON, Canada; 2Servicio de Analisis Clinicos, Hospital Universitario de Salamanca, Salamanca, Spain; 3UTCA Servicio Endocrino y Nutricion, Hospital Universitario de Salamanca, Salamanca, Spain.

157-P
INTERLEUKINES GENES POLIMORPHISM IN PATIENTS WITH BLADDER CANCER.
Alberto J. Leon1, Victoriano J. Leon2, Javier Garcia3, Manuel Urrutia3. 1Division of Experimental Therapeutics, Toronto General Research Institute, Toronto, ON, Canada; 2Servicio de Analisis Clinicos, Hospital Universitario de Salamanca, Salamanca, Spain; 3Servicio de Urologia, Hospital Universitario de Salamanca, Salamanca, Spain.

158-P
HLA DR4 WITHOUT DR53.
Alan M. Luger1, Melissa A. Steele1, Marcelo Fernandez-Vina2, Dolly Tyan2. 1Transplant, Jewish Hospital, Louisville, KY, USA; 2HLA Laboratory, Stanford University, La Jolla, CA, USA.

159-P
IMMUNOGENOMICS DATA ANALYSIS WORKING GROUP (IDAWG) SURVEY OF IMMUNOGENOMIC DATA MANAGEMENT AND ANALYSIS METHODS.
Steven J. Mack, Jill A. Hollenbach. Center for Genetics, Children’s Hospital Oakland Research Institute, Oakland, CA, USA.
Abstracts

160-P
EFFECT OF TIME AFTER BLOOD DRAW AND ANTI-COAGULANT ON LYMPHOCYTE SUBSET AND MYELOID CELL ENRICHMENT WITH RosetteSep™ AND SepMate™.

161-P
REAL TIME (AND COST) SAVINGS WITH REAL TIME PCR DECEASED DONOR MOLECULAR TYPING.
Maureen Miller, Tod Alberghini, Michael Rewinski, Laurine Bow. Transplant Immunology Laboratory, Hartford Hospital, Hartford, CT, USA.

162-P
PCR-SSOP AMBIGUITIES AND THEIR DIFFERENT RESOLUTIONS.
Alessandro Pirri, Sonia Maria C.M. Costa, Maria da Graça Bicalho. Genetics, Federal University of Paraná, Curitiba, Paraná, Brazil.

163-P
DESCRIPTION OF ALLELE LEVEL HLA-DRB4 CONTAINING DRB1-DRB4-DQA1-DQB1 HAPLOTYPES.
Patrick Reville, Dawn Thomas, Paul Kawczak, Aiwen Zhang, John McMichael, Medhat Askar. Allogen Laboratories, Cleveland Clinic, Cleveland, USA.

164-P
CAN WE PREDICT HLA-DQA1 ALLELE ASSIGNMENTS BASED ON PUBLISHED DRB1/DQB ASSOCIATION DATA?
Nebila Abdulwahab, Adam Schoen, Matthew Kott, Nicholas Dipaola. Clinical Histocompatibility Laboratory, The Ohio State University Wexner Medical Center, Columbus, OH, USA.

165-P
HLA-DRB1 AND -DQB1 ALLELE DISTRIBUTION BASED ON A SOUTH BRAZILIAN POPULATION OF BONE MARROW DONORS.
Carlos F. Alves, Carolina Kneib, Heloisa Salomão, Cristina Q.C. von Glehn, Michelle F. Susin. Transplant Immunology Laboratory, Pontifical Catholic University of Parana, Curitiba, Parana, Brazil.

166-P
WOULD BE HLA-C*15 GENE RELATED WITH THE RESISTANCE OF DUST MITES SENSITIVE INDIVIDUALS?
Abstracts

167-P
A ONE-PASS DNA SEQUENCING STRATEGY AT RECRUITMENT OF HEMATOPOIETIC STEM CELL DONORS – RETHINKING TYPING REQUIREMENTS.
Bin Tu, Nuri Cha, Phillip Posch, Jennifer Ng, Carolyn K. Hurley. CW Bill Young Marrow Recruitment and Research Program, Georgetown University, Rockville, MD, USA.

168-P
ASSOCIATION OF HLA AND MICA ALLELES WITH LEPROSY IN FAMILIES FROM AN ENDEMIC AREA OF THE NORTH OF BRAZIL.
Luciana Ribeiro Jarduli1, Hugo Vicentin Alves1, Fabiana Covolo de Souza2, Elaine Valim Camarinhã Marcos2, Ana Carla Pereira2, Ida Maria Foschiani Dias-Baptista2, Geovana Broto Ramos2, Vinícius Medeiros Fava3, Marcelo Távora Mira3, Milton Ozório Moraes4, Marcos da Cunha Lopes Virmond2, Jeanne Eliete Laguilá Visentainer1. 1Departamento de Ciências Básicas e da Saúde, Laboratório de Imunogenética, Universidade Estadual de Maringá, Maringá, Paraná, Brazil; 2Secretaria do Estado de Saúde, Instituto Lauro Souza Lima, Bauru, SP, Brazil; 3Centro de Ciências Biológicas e da Saúde, Pontifícia Universidade Católica do Paraná, Curitiba, Paraná, Brazil; 4Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.

169-P
SUCCESSFUL DESENSITIZATION IN A HEART TRANSPLANT PATIENT.
Kevin M. Burns, Geoffrey A. Land, Smaroula Dilioglou. Department of Pathology and Genomic Medicine, The Methodist Hospital, Houston, TX, USA.

170-P
SUCCESSFUL RE-TRANSPLANTATION OF AN ADULT SMALL BOWEL TRANSPLANT RECIPIENT IN THE SETTING OF POSITIVE CDC CROSSMATCH.
Catherine Gebhart, James Wisecarver. Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.

171-P
LIFE-THREATENING IMMUNE THROMBOCYTOPENIA DUE TO PREGNANCY SENSITIZATION. CASE STUDY.
Diana M. Girnita1, Rajan Lakhia1, Paul Brailey2, Elisabeth Portwood2, Alin L. Girnita2. 1Internal Medicine, The Christ Hospital, Cincinnati, OH, USA; 2Surgery, University of Cincinnati, Cincinnati, OH, USA.

172-P
POST TRANSPLANT DONOR SPECIFIC ANTIBODY: CORRELATION OF MFI TO FLOW CROSSMATCH RESULTS.
Anne Halpin1, Laurie Brassard1, Sandra Cockfield2, Nicole Hengerer1, Patricia Campbell1. 1Laboratory Medicine, University of Alberta Hospital, Edmonton, AB, Canada; 2Medicine, Division of Nephrology, University of Alberta, Edmonton, AB, Canada.

173-P
RECYCLING ALLOGRAFT KIDNEYS: MONITORING FOR HLA ANTIBODIES.
Judy Howe, Joan Martell, Adriana Zeevi, John Lunz. Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Abstracts

174-P
NEW DQB1 ALLELE PROBABLY ASSOCIATED WITH B*48:01/DRB1*12:01/DRB3*01.
Carrera Kostur¹, Luz Stamm¹, Judy Zachariassen², Patti Wright¹, Noureddine Berka¹, Sofia Tavoularis³. ¹Tissue Typing, Calgary Lab Services, Calgary, AB, Canada; ²Alberta Blood & Marrow Transplant Program, Tom Baker Cancer Centre, Calgary, AB, Canada; ³Head Office HLA Laboratory, Canadian Blood Services, Ottawa, ON, Canada.

175-P
ACUTE HEART TRANSPLANT REJECTION IN THE PRESENCE OF APPARENTLY WEAK, NON-COMPLEMENT-FIXING DONOR-SPECIFIC ANTIBODIES DETECTED AT THE TIME OF TRANSPLANT.
Anthony Nizio¹, Paul Mather², Beth Colombe¹. ¹Clinical Laboratory -Tissue Typing, Thomas Jefferson University Hospital, Philadelphia, PA, USA; ²Department of Medicine-Cardiology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.

176-P
CASE STUDY OF A MULTIPLE STEM CELL’S RECIPIENT WITH ACUTE LYMPHOBLASTIC LEUKEMIA.
Lucie Richard, Diane Roy. Stem Cell and Reference Laboratory, Hema-Quebec, Saint-Laurent, QC, Canada.

177-P
UNACCEPTABLE ANTIGEN DILEMMA FOR LUNG PATIENT.
Cheryl L. Thompson¹, Donna Phelan¹, Gerald Morris², T. Mohanakumar³. ¹HLA Laboratory, Barnes-Jewish Hospital, St. Louis, MO, USA; ²Department of Pathology and Immunology, Washington University, St. Louis, MO, USA; ³Department of Surgery, Washington University, St. Louis, MO, USA.

178-P
SBT AND RSSO FAIL TO DETECT HETEROZYGOUS HLA LOCI IN TWO AML PATIENTS.
Cheryl L. Thompson¹, Donna Phelan¹, Gerald Morris², T. Mohanakumar³. ¹HLA Laboratory, Barnes-Jewish Hospital, St. Louis, MO, USA; ²Department of Pathology and Immunology, Washington University, St. Louis, MO, USA; ³Department of Surgery, Washington University, St. Louis, MO, USA.

179-P
UNEXPECTED T CELL POSITIVE AND B CELL NEGATIVE FLOW CYTOMETRY CROSSMATCH IN A KIDNEY TRANSPLANT PATIENT.
Gansuvd Balgansuren, Adella Clark, Giles T. Crews, Melissa Baker, Wendy E. Wegner, Dong-Feng Chen. Department of Pathology and Clinical Laboratories, Duke University Medical Center, Durham, NC, USA.

180-P
CHARACTERIZATION OF PAN-DR ANTIBODIES DETECTED IN TWO TRANSPLANT CANDIDATES.
Wendy E. Wegner, Runying Tian, Giles T. Crews Jr., Adella Clark, Dong-Feng Chen. Department of Pathology and Clinical Laboratories, Duke University Medical Center, Durham, NC, USA.
Abstracts

181-P
REJECTION OF A KIDNEY TRANSPLANT AFTER IVIG TREATMENT FOR BK NEPHROPATHY.
Qingyong Xu1,4, Rahul Mainra2, Rajni Chibbar1, Jiangping Li3, Ahmed shoker2. 1Pathology & Lab Medicine, University of Saskatchewan, Saskatoon, Canada; 2Medicine, University of Saskatchewan, Saskatoon, Canada; 3Pathology & Lab Medicine, The Ottawa General Hospital, Ottawa, Canada; 4Lab Medicine, St. Paul’s Hospital, Saskatoon, Canada.

182-P
LIVING SIMULTANEOUS DOUBLE LUNG TRANSPLANT RECIPIENT WITH POST-TRANSPLANT DQA DSA TOWARDS ONE DONOR.
Christine Yamniuk, Anne Halpin, Patricia Campbell, Luis Hidalgo. Laboratory Medicine & Pathology, University of Alberta Hospital, Edmonton, AB, Canada.

183-P
OUTCOMES FOR RENAL TRANSPLANTATION IN INDIGENOUS AUSTRALIANS.
Tim Emery1, Michael Burke2, Toby Coates2. 1South Australian Transplantation and Immunogenetics Service, Australian Red Cross Blood Service, Adelaide, South Australia, Australia; 2Central and Northern Adelaide Renal Transplant Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.

184-P
WEST NILE VIRUS PEPTIDE PRESENTATION BY HLA CLASS I.
Saghar Kaabinejadian1, Stephen R. Vernon1, Curtis P. McMurtrey1, Lydgia A. Jackson1, Wilfried Bardet1, Danijela Mojsilovic1, Fredda B. Schafer1, Kenneth W. Jackson1, Rico Buchli2, William H. Hildebrand1. 1Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; 2Pure Protein LLC, Oklahoma City, OK, USA. Buchli: Pure Protein L.L.C.: Employee.

185-P
DEDUCTION OF MISMATCHED DONOR HLA FROM URINE SAMPLES OF KIDNEY TRANSPLANTED RECIPIENTS.
Ricky Lau1, Janette Kwok1, Gavin Chan2, K.T. Tam1, M.F. Lam3, Maggie Mok3, W.L. Chak4, Cheuk Au5, K.W. Chan2, K.F. Chau6, Matthew Tong6, T.M. Chan3. 1Transplantation and Immunogenetics, Queen Mary Hospital, Hong Kong SAR, China; 2Department of Pathology, Queen Mary Hospital, Hong Kong SAR, China; 3Department of Medicine, The University of Hong Kong, Hong Kong SAR, China; 4Department of Medicine, Queen Elizabeth Hospital, Hong Kong SAR, China; 5Department of Medicine & Geriatrics, Princess Margaret Hospital, Hong Kong SAR, China.

186-P
STORAGE OF DNA ON FILTER PAPER: QUALITY TEST ON SAMPLES KEEPING 10 YEARS.
Victoriano J. Leon1, Alberto J. Leon2, Amador Crego1. 1Servicio de Analisis Clinicos, Hospital Universitario de Salamanca, Salamanca, Spain; 2Division of Experimental Therapeutics, Toronto General Research Institute, Toronto, ON, Canada.
187-P
AVOIDING COAGULATION INTERFERENCE OF SERUM-BASED ASSAYS MID-TEST WITHOUT SAMPLE DILUTION: A QUICK METHOD TO SCREEN FOR AND REMOVE FIBRINOGEN IN PARTIALLY COAGULATED SERUM.
Olga Menninger¹, Shalini Pereira¹,²,³. ¹Clinical Immunogenetics Laboratory, Seattle Cancer Care Alliance, Seattle, WA, USA; ²Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; ³Department of Laboratory Medicine, University of Washington, Seattle, WA, USA.

188-P
GENOTYPING CYP2C19/PON1 POLYMORPHISMS USING SEQUENOM TECHNOLOGY FOR CHARACTERIZATION OF RISK GENOTYPES FOR CLOPIDOGREL RESPONSE IN CZECH PATIENTS WITH CORONARY STENTING.
Martin Petrek¹,²,³, Petra Schneiderova¹, Eva Kriegova¹, Jana Petrkova²,³. ¹Clinical Molecular Pathology - Cardiogenomics Lab, University Hospital, Olomouc, Czech Republic; ²Internal Medicine I - Cardiology, University Hospital, Olomouc, Czech Republic; ³Lab. of Immunogenomics and Immunoproteomics, Faculty of Medicine and Dentistry Palacky University, Olomouc, Czech Republic.

189-P
AN XML EXPORT OF THE IMGT/HLA DATABASE.
James Robinson¹, Jane Pollack², Adrienne Walts², Joel Schneider², Read Fritsch², Anthony Barber², John Freeman², Martin Maiers², Steven G.E. Marsh¹. ¹HLA Informatics Group, Anthony Nolan Research Institute, London, United Kingdom; ²Bioinformatics, National Marrow Donor Program, Minneapolis, USA.

190-P
EVALUATION OF CELL ISOLATION METHODS FOR FLOW CROSSMATCH OF DECEASED SOLID ORGAN TRANSPLANTATION.
Giles T. Crews, Wendy E. Wegner, Gansuvd Balgansuren, Dong-Feng Chen. Department of Pathology and Clinical Laboratories, Duke University Medical Center, Durham, NC, USA.
Abstracts

Late Breaking Abstracts

1001-LB
INTERPRETATION AND MEANING OF ANTI-HLA ANTIBODIES DETECTED BY FLUORESCENCE TECHNIQUES.
Terry Harville. University of Arkansas for Medical Sciences, Little Rock, AR, USA.

1002-LB
ACE POLYMORPHISM IN ASTHMATIC PATIENTS.
Margarida Cortez1; Joana Ferreira2; Leonor Lopes3; Manuel Pereira-Barbosa1; Manuel Bicho2. 1ImmuNoAllergy Department CHLN-HSM, Portugal, 2Genetic Department- Lisbon Medical School- Lisbon, Portugal.

1003-LB
INFLUENCE OF KILLER-CELL IMMUNOGLOBULIN-LIKE RECEPTORS GENOTYPED IN BRAZILIAN POPULATIONS WITH LEUKEMIA: DIFFERENCES BETWEEN ACUTE LEUKEMIA AND CHRONIC LEUKEMIA.
Araujo Margareth Batistella1, Correa Carlos Roberto2, Fernandes Tania Aparecida Rodrigues1, Kraemer Maria Helena Stangler1. 1HLA Molecular Biology Laboratory1, Public Health Department2, 2School of Medical Science, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.

1004-LB
THE ROLE OF DE NOVO DQ DONOR SPECIFIC ANTIBODIES (DSA), IgG SUBCLASSES AND C1q IN KIDNEY TRANSPLANT OUTCOME.
Maria Cecilia Freitas1, Mikki Ozawa2, Anh Nguyen2, Nori Sasaki2, Matthew Everly2, Lorita M Rebello2, Paul I Terasaki1. 1Terasaki Foundation Laboratory, Los Angeles, CA, USA. 2One Lambda Inc., Canoga Park, CA, USA.

1005-LB
OLERUP US XM-ONE PROFICIENCY TESTING (PT) PROGRAM UPDATE
Manuel Carreño1, Annette Jacksson2, Bruno Vanherberghen3, Håkan Hall3, 1Olerup Inc., West Chester, PA, USA., 2John Hopkins University, Baltimore, MD, USA., 3AbSorber AB, Stockholm, Sweden.

1006-LB
UNEXPLAINED POSITIVE REACTIONS WITH ONE LAMBDA, FLOWPRATM LOT #18.
Robert A. Bray, Linda McLachlan, Pam Chapman, Nalaja Marcus and Howard M. Gebel. Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA.

1007-LB
A NEW C1q-FLOW CROSSMATCH FOR DETECTING DONOR SPECIFIC COMPLEMENT FIXING ANTIBODIES (CFAb).
Flavia Sequeira, Dolly Tyan, Ge Chen. Department of Pathology, Stanford School of Medicine, Palo Alto, CA, USA.
Abstracts

1008-LB
FIVE-YEAR EVALUATION OF BUCCAL SWAB SAMPLES STORED AT VARIOUS TEMPERATURES.
Sofia Tavoularis, Edite Ribeiro, Heidi Elliott. 1Canadian Blood Services, Head Office, Ottawa, Canada. 2University of Ottawa, Faculty of Medicine, Ottawa, Canada.

1009-LB
HLA TYPING FROM NEXT GENERATION SEQUENCING DATA.

1010-LB
C1Q-BINDING ANTIBODY REACTIVITY TOWARDS A MISMATCHED HLA-DPA1 EPITOPE IS ASSOCIATED WITH ACUTE RENAL ALLOGRAFT REJECTION.
Beata Mierzejewska1, Paul Schroder2, Annette Blair2, Connie Smith2, Rene Duquesnoy1, Marilyn Marari3, Michael Rees1, Stanislaw Stepkowski2. 1Department of Urology, University of Toledo, Toledo, OH, USA. 2Department of Microbiology and Immunology, University of Toledo, Toledo, OH. 3Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA.

1011-LB
HLA GENOTYPING DIRECTLY FROM DRIED BLOOD SPOTS USING LIFECODES SSO TYPING KIT.
Gyanendra Kumar, Amritha Bhat, and Bryan Ray. Gen-Probe Transplant Diagnostics Inc, 550 West Avenue, Stamford, CT, USA.

1012-LB
ENHANCED RESOLUTION OF LIFECODES HLA-C eRES SSO TYPING KIT BY THE ADDITION OF 22 NEW PROBES.
Gyanendra Kumar, Sarah Boucher, Jian Qin, and Bryan Ray. Gen-Probe Transplant Diagnostics Inc, 550 West Avenue, Stamford, CT, USA.

1013-LB
INCREASED ANTIBODY DETECTION WITH EXPANDED PANEL OF ANTIGENS IN LIFECODES CLASS II IDv2 (LM2Q)
Ben Boldt1, Monica Burton2, Felecia McDougan2, Pamela Kimball2, Jennie W. Stewart3, Sharlie B. Brown3, and Michael Gautreaux1. 1Gen-Probe Incorporated, San Diego, CA, USA. 2Virginia Commonwealth University, Richmond, VA, USA. 3Wake Forest School of Medicine, Winston-Salem, NC, USA.

1014-LB
DTT TREATMENT OF SERA IS EFFECTIVE IN REMOVING INTERFERENCE BY THE C1 COMPONENT OF COMPLEMENT IN SINGLE ANTIGEN AND C1q ASSAYS.
Katharine Spanjer, Brian Freed, Kelly Greenlee, Linda Cagle, Garrett Hedlund, Zachary Swensen, Dianne McLaughlin, Sarah Bruno, Lindsay McCormick, Kristen Blackburn, Kristen Schultz. ClinImmune Labs, Aurora, CO, USA.
Abstracts

1015-LB
ADDITION OF 6 NEW SSO PROBES TO IMPROVE RESOLUTION OF LIFECODES HLA-DQB.
Shalaka Patel, Amy Wayland-Smith, Bryan Ray. Gen-Probe Transplant Diagnostics, San Diego, CA, USA.

1016-LB
ADDITION OF 10 NEW SSO PROBES TO IMPROVE RESOLUTION OF LIFECODES HLA-DRB1 eRES.
Shalaka Patel, Anesha Sledge, Bryan Ray. Gen-Probe Transplant Diagnostics, San Diego, CA, USA.

1017-LB
DETECTING HLA CLASS1 AND CLASS2 NULL ALLELES BY SOLID-PHASE DNA ASSAY.
Jian Qin, Shikha Shukla, Amanda Smith, Bryan Ray. Gen-Probe Transplant Diagnostics, San Diego, CA, USA.

1018-LB
PRELIMINARY EVALUATION OF THE BIOTEK® MICROPLATE STRIP WASHER FOR USE WITH SOLID PHASE ASSAYS.
Justin Mostecki, Hari Malireddy, Lalita Shivraj, Bryan Ray. Gen-Probe Transplant Diagnostics, San Diego, CA, USA.

1019-LB
COMPARISON OF THE PERFORMANCE CHARACTERISTICS OF COMMERCIALLY AVAILABLE SOLID PHASE SINGLE ANTIGEN REAGENTS.
R. Carlin Walsh, Jennifer R. Zitzner, Andrea A. Zimmerman, Anat R. Tambur. Comprehensive Transplant Center, Northwestern University, Chicago, IL, USA.

1020-LB
PREDICTION OF POSITIVE FLOW CROSSMATCH BY USING MEAN FLUORESCENCE INTENSITY OF LUMINEX SINGLE ANTIGEN BEAD ASSAY.
Liang Wan, Wendy E Wegner, Dong-Feng Chen. Duke University Medical Center, Department of Pathology and Clinical Laboratories, Durham, NC, USA.

1021-LB
KIR2DL2 AND KIR3DS1 AND IL28B ASSOCIATION WITH HCV RESOLUTION.
Gustavo Fabricio-Silva1, Magda Castilho1, Juliana Cardoso-Oliveira1, Bruno Almeida2, Renata Perez3, Fatima Figueiredo3, Raquel Al-Cici2, Luis Cristovao Porto1. 1 Histocompatibility and Cryopreservation Laboratory, and 2Gastroenterology Service, Rio de Janeiro State University, Brazil.
Abstracts

1022-LB
UNCOVERING THE MECHANISMS OF HIGH RATE OF CLINICAL REJECTION OF KIDNEY TRANSPLANT IN HIV PATIENTS.
Jacques Juedy1,2. 1Haiti Transplant Program, 1Port-au-Prince, Haiti, 2University of Miami Leonard Miller School of Medicine, Miami, FL, USA.

1023-LB
HLA-C MISMATCH AND GRAFT-VERSUS-HOST DISEASE.
Matilde Romero, Anna Paula Villela, Christina Nogueira, Luis Fernando Bouzas, Eliana Abdelhay. Bone Marrow Unit Laboratory Division - INCA, Brazil.

1024-LB
HLA DQA AND DQB EPITOPES: DETERMINED BY ALLOANTIBODIES ADSORBED AND ELUTED FROM RECOMBINANT HLA DQ SINGLE ANTIGEN CELL LINES AND THE ANTIBODIES’ REACTION PATTERNS WITH HLA DQ SINGLE ANTIGEN BEADS.
Nadim El-Awar1, Khalid Almeshari2, Fadi Alzayer2, Maha Alharbi2, Moheeb Alawami2, Anh Nguyen1, Paul I. Terasaki3. 1One Lambda Inc., Canoga Park, USA, 2King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia, 3Terasaki Laboratory Foundation, Los Angeles, USA.

1025-LB
HIGH THROUGHPUT HLA 454 SEQUENCING USING THE FLUIDIGM® ACCESS ARRAY TM SYSTEM AND CONEXIO ASSIGNTM-ATF SOFTWARE.
Priscilla V. Moonsamy1, Timothy Williams2, Persia Bonella2 Cherie L. Holcomb1, Granlland Hillman1, Gregory S. Turenchalk3, Lisbeth A. Blake3, Birgitte B. Simen3, Damian Goodridge4, Amy Hamilton5, Andrew P. May5, Henry A. Erlich1. 1Roche Molecular Systems, Inc., Pleasanton, CA., 2Children’s Hospital Oakland Research Institute, Oakland, CA., USA. Life Sciences, a Roche company, Branford, CT., 4Conexio Genomics, Perth, Australia., 5Fluidigm Corporation, South San Francisco, CA, USA.

1026-LB
DISCREPANCY BETWEEN CDC-AHG CROSSMATCH AND FLOW CYTOMETRY CROSS MATCH WITH SERUM SHOWING MULTIPLE CLASS I AND CLASS II HLA ANTIBODIES: NON-COMPLEMENT BINDING IgG ANTIBODIES?
Siva Kanangat, Michele Prod, Maria Oppermann, Sylvia Piggot, Ina Kurbegovic, Edward Hollinger and Stephen Jensik. RUSH University Medical Center, Chicago, IL, USA.
Convention Center Floor Plans

Exhibit Hall C, Level 1
Convention Center Floor Plans

Level 1
Convention Center Floor Plans

Level 2
Convention Center Floor Plans

**Level 3**
Future Annual Meetings

39th Annual Meeting
November 17 – 21, 2013
Sunday – Thursday
Sheraton Chicago Hotel & Towers
Chicago, Illinois

40th Annual Meeting
October 20 – 24, 2014
Sheraton Denver Downtown Hotel
Denver, Colorado